<!DOCTYPE html>
<html>
<head>

<script id="f5_cspm">
(function(){var f5_cspm={f5_p:'NJLLLDAMCLEAJNDDEKDIBLMKEJFNEHBCNIENAHLDHFFBHLDANMHPHOGBNJCACNODLJINIDMBNJKLOINCAKPCNDNGAMEOKCECAGONKBAFKLBANFIBLCHPDPMLMLKCMCFI',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}
f5_cspm.go();}());
</script>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - FLUCONAZOLE- fluconazole tablet</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">FLUCONAZOLE- fluconazole
tablet<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFLUCONAZOLE%2D%20Fluconazole%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dcf26b007%2Ddf4f%2D4936%2Db2d3%2D183969761f69%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=image-01.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=image-01.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
src=
"image.cfm?type=img&amp;name=image-01.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=image-02.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=image-02.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
src=
"image.cfm?type=img&amp;name=image-02.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=image-03.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=image-03.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
src=
"image.cfm?type=img&amp;name=image-03.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=image-04.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="3"><img id="zoom_4" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=image-04.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
src=
"image.cfm?type=img&amp;name=image-04.jpg&amp;setid=cf26b007-df4f-4936-b2d3-183969761f69"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22FLUCONAZOLE%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=FLUCONAZOLE"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=FLUCONAZOLE"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUCONAZOLE[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUCONAZOLE/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUCONAZOLE/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUCONAZOLE/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=FLUCONAZOLE[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00327&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0378-2514-93, 0378-2516-93, 0378-2518-32,
0378-2518-96, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id=
"item-code-s"><span>0378-2520-93</span></span></div>
</li>
<li><strong>Packager:</strong> Mylan Pharmaceuticals Inc.</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">Abbreviated New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated November 30, 2012</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;type=pdf&amp;name=cf26b007-df4f-4936-b2d3-183969761f69"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;type=zip&amp;name=FLUCONAZOLE"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name=
"i4i_description_id_c3a165d9-bb2c-44e4-b3ce-4d32de2aa0fb" id=
"i4i_description_id_c3a165d9-bb2c-44e4-b3ce-4d32de2aa0fb"></a>
<a name="section-1" id="section-1"></a>
<p class="First">Fluconazole, the first of a new subclass of
synthetic triazole antifungal agents, is available as tablets for
oral administration.</p>
<p>Fluconazole is designated chemically as
2,4-difluoro-α,α<span class=
"Sup">1</span>-bis(1H-1,2,4-triazol-l-ylmethyl) benzyl alcohol with
a molecular formula of C<span class="Sub">13</span>H<span class=
"Sub">12</span>F<span class="Sub">2</span>N<span class=
"Sub">6</span>O and molecular weight 306.3. The structural formula
is:</p>
<div class="Figure"><a name="id640" id="id640"></a> <img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=b75dbe49-9a2a-4f8a-916a-42297c0b8f4f-01.jpg"
alt="Structural Formula"></div>
<p>Fluconazole, USP is a white crystalline solid which is slightly
soluble in water and saline.</p>
<p>Each tablet, for oral administration, contains 50 mg, 100 mg,
150 mg or 200 mg of fluconazole, USP. In addition, each tablet
contains the following inactive ingredients: anhydrous lactose,
colloidal silicon dioxide, croscarmellose sodium, D&amp;C Yellow
No. 10 Aluminum Lake, magnesium stearate, microcrystalline
cellulose, povidone and sodium lauryl sulfate.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name=
"i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96"
id=
"i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
</a> <a name="section-2" id="section-2"></a>
<div class="Section" data-sectioncode="43682-4"><a name=
"i4i_pharmacokinetics_id_2a13533c-60b8-4631-9a29-979168e6e5ad" id=
"i4i_pharmacokinetics_id_2a13533c-60b8-4631-9a29-979168e6e5ad"></a>
<a name="section-2.1" id="section-2.1"></a>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">The pharmacokinetic properties of fluconazole are
similar following administration by the intravenous or oral routes.
In normal volunteers, the bioavailability of orally administered
fluconazole is over 90% compared with intravenous administration.
Bioequivalence was established between the 100 mg tablet and both
suspension strengths when administered as a single 200 mg dose.</p>
<p>Peak plasma concentrations (C<span class="Sub">max</span>) in
fasted normal volunteers occur between 1 and 2 hours with a
terminal plasma elimination half-life of approximately 30 hours
(range: 20 to 50 hours) after oral administration.</p>
<p>In fasted normal volunteers, administration of a single oral 400
mg dose of fluconazole leads to a mean C<span class=
"Sub">max</span> of 6.72 mcg/mL (range: 4.12 to 8.08 mcg/mL) and
after single oral doses of 50 mg to 400 mg, fluconazole plasma
concentrations and AUC (area under the plasma concentration-time
curve) are dose proportional.</p>
<p>The C<span class="Sub">max</span> and AUC data from a
food-effect study involving administration of fluconazole tablets
to healthy volunteers under fasting conditions and with a high-fat
meal indicated that exposure to the drug is not affected by food.
Therefore, fluconazole may be taken without regard to meals. (See
<a href=
"#i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14">DOSAGE
AND ADMINISTRATION</a>.)</p>
<p>Administration of a single oral 150 mg tablet of fluconazole to
ten lactating women resulted in a mean C<span class=
"Sub">max</span> of 2.61 mcg/mL (range: 1.57 to 3.65 mcg/mL).</p>
<p>Steady-state concentrations are reached within 5 to 10 days
following oral doses of 50 mg to 400 mg given once daily.
Administration of a loading dose (on day 1) of twice the usual
daily dose results in plasma concentrations close to steady-state
by the second day. The apparent volume of distribution of
fluconazole approximates that of total body water. Plasma protein
binding is low (11% to 12%). Following either single- or
multiple-oral doses for up to 14 days, fluconazole penetrates into
all body fluids studied (see table below). In normal volunteers,
saliva concentrations of fluconazole were equal to or slightly
greater than plasma concentrations regardless of dose, route, or
duration of dosing. In patients with bronchiectasis, sputum
concentrations of fluconazole following a single 150 mg oral dose
were equal to plasma concentrations at both 4 and 24 hours post
dose. In patients with fungal meningitis, fluconazole
concentrations in the CSF are approximately 80% of the
corresponding plasma concentrations.</p>
<p>A single oral 150 mg dose of fluconazole administered to 27
patients penetrated into vaginal tissue, resulting in tissue:plasma
ratios ranging from 0.94 to 1.14 over the first 48 hours following
dosing.</p>
<p>A single oral 150 mg dose of fluconazole administered to 14
patients penetrated into vaginal fluid, resulting in fluid:plasma
ratios ranging from 0.36 to 0.71 over the first 72 hours following
dosing.</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="21%">
<col width="45%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="2">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">*</a></dt>
<dd>Relative to concurrent concentrations in plasma in subjects
with normal renal function.</dd>
<dt><a href="#footnote-reference-2" name="footnote-2" id=
"footnote-2">†</a></dt>
<dd>Independent of degree of meningeal inflammation.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" valign="top"></td>
<td class="Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Ratio of Fluconazole Tissue
(Fluid)/Plasma</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Tissue or Fluid</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Concentration</span><a class=
"Sup" href="#footnote-1" name="footnote-reference-1" id=
"footnote-reference-1">*</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Cerebrospinal fluid<a class="Sup" href=
"#footnote-2" name="footnote-reference-2" id=
"footnote-reference-2">†</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">0.5 to 0.9</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Saliva</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Sputum</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Blister fluid</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Urine</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">10</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Normal skin</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">10</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nails</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Blister skin</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Vaginal tissue</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Vaginal fluid</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">0.4 to 0.7</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>In normal volunteers, fluconazole is cleared primarily by renal
excretion, with approximately 80% of the administered dose
appearing in the urine as unchanged drug. About 11% of the dose is
excreted in the urine as metabolites.</p>
<p>The pharmacokinetics of fluconazole are markedly affected by
reduction in renal function. There is an inverse relationship
between the elimination half-life and creatinine clearance. The
dose of fluconazole may need to be reduced in patients with
impaired renal function. (See <a href=
"#i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14">DOSAGE
AND ADMINISTRATION</a>.) A 3 hour hemodialysis session decreases
plasma concentrations by approximately 50%.</p>
<p>In normal volunteers, fluconazole administration (doses ranging
from 200 mg to 400 mg once daily for up to 14 days) was associated
with small and inconsistent effects on testosterone concentrations,
endogenous corticosteroid concentrations, and the ACTH-stimulated
cortisol response.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"i4i_pharmacokinetics_id_0dd2962b-21d0-4751-8139-2683c98a2889" id=
"i4i_pharmacokinetics_id_0dd2962b-21d0-4751-8139-2683c98a2889"></a>
<a name="section-2.2" id="section-2.2"></a>
<h2>Pharmacokinetics in Children</h2>
<p class="First">In children, the following pharmacokinetic data
{Mean(%cv)} have been reported:</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="14%">
<col width="13%">
<col width="15%">
<col width="10%">
<col width="13%">
<col width="14%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold">Age<br>
Studied</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Dose<br>
(mg/kg)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Clearance<br>
(mL/min/kg)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Half-life<br>
(Hours)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">C<span class=
"Sub">max</span><br>
(mcg/mL)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Vdss<br>
(L/kg)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">9 months to<br>
13 years</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Single-Oral<br>
2 mg/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.40 (38%)<br>
N = 14</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">25.0<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">2.9 (22%)<br>
N = 16</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">-</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">9 months to<br>
13 years</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Single-Oral<br>
8 mg/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.51 (60%)<br>
N = 15</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">19.5<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">9.8 (20%)<br>
N = 15</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">-</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">5 to 15 years<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Multiple IV<br>
2 mg/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.49 (40%)<br>
N = 4</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">17.4<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">5.5 (25%)<br>
N = 5</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.722 (36%)<br>
N = 4</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">5 to 15 years<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Multiple IV<br>
4 mg/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.59 (64%)<br>
N = 5</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">15.2<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">11.4 (44%)<br>
N = 6</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.729 (33%)<br>
N = 5</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">5 to 15 years<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Multiple IV<br>
8 mg/kg</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">0.66 (31%)<br>
N = 7</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">17.6<br></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">14.1 (22%)<br>
N = 8</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1.069 (37%)<br>
N = 7</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>Clearance corrected for body weight was not affected by age in
these studies. Mean body clearance in adults is reported to be 0.23
(17%) mL/min/kg.</p>
<p>In premature newborns (gestational age 26 to 29 weeks), the mean
(%cv) clearance within 36 hours of birth was 0.180 (35%, N = 7)
mL/min/kg, which increased with time to a mean of 0.218 (31%, N =
9) mL/min/kg 6 days later and 0.333 (56%, N = 4) mL/min/kg 12 days
later. Similarly, the half-life was 73.6 hours, which decreased
with time to a mean of 53.2 hours 6 days later and 46.6 hours 12
days later.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"i4i_pharmacokinetics_id_1cda5614-0c01-4a45-8924-a90c9a071890" id=
"i4i_pharmacokinetics_id_1cda5614-0c01-4a45-8924-a90c9a071890"></a>
<a name="section-2.3" id="section-2.3"></a>
<h2>Pharmacokinetics in Elderly</h2>
<p class="First">A pharmacokinetic study was conducted in 22
subjects, 65 years of age or older receiving a single 50 mg oral
dose of fluconazole. Ten of these patients were concomitantly
receiving diuretics. The C<span class="Sub">max</span> was 1.54
mcg/mL and occurred at 1.3 hours post dose. The mean AUC was 76.4 ±
20.3 mcg•h/mL, and the mean terminal half-life was 46.2 hours.
These pharmacokinetic parameter values are higher than analogous
values reported for normal young male volunteers. Coadministration
of diuretics did not significantly alter AUC or C<span class=
"Sub">max</span>. In addition, creatinine clearance (74 mL/min),
the percent of drug recovered unchanged in urine (0 to 24 hr, 22%)
and the fluconazole renal clearance estimates (0.124 mL/min/kg) for
the elderly were generally lower than those of younger volunteers.
Thus, the alteration of fluconazole disposition in the elderly
appears to be related to reduced renal function characteristic of
this group. A plot of each subject’s terminal elimination half-life
versus creatinine clearance compared with the predicted half-life –
creatinine clearance curve derived from normal subjects and
subjects with varying degrees of renal insufficiency indicated that
21 of 22 subjects fell within the 95% confidence limit of the
predicted half-life – creatinine clearance curves. These results
are consistent with the hypothesis that higher values for the
pharmacokinetic parameters observed in the elderly subjects
compared with normal young male volunteers are due to the decreased
kidney function that is expected in the elderly.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1" id=
"i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1"></a> <a name=
"section-2.4" id="section-2.4"></a>
<h2>Drug Interaction Studies</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_737e8b13-ec74-461a-a563-26989ac2e8fc" id=
"i4i_section_id_737e8b13-ec74-461a-a563-26989ac2e8fc"></a> <a name=
"section-2.4.1" id="section-2.4.1"></a>
<h3><span class="Bold"><span class="Italics">Oral
Contraceptives</span></span></h3>
<p class="First">Oral contraceptives were administered as a single
dose both before and after the oral administration of fluconazole
50 mg once daily for 10 days in ten healthy women. There was no
significant difference in ethinyl estradiol or levonorgestrel AUC
after the administration of 50 mg of fluconazole. The mean increase
in ethinyl estradiol AUC was 6% (range: -47% to 108%) and
levonorgestrel AUC increased 17% (range: -33% to 141%).</p>
<p>In a second study, twenty-five normal females received daily
doses of both 200 mg fluconazole tablets or placebo for two, 10-day
periods. The treatment cycles were one month apart with all
subjects receiving fluconazole during one cycle and placebo during
the other. The order of study treatment was random. Single doses of
an oral contraceptive tablet containing levonorgestrel and ethinyl
estradiol were administered on the final treatment day (day 10) of
both cycles. Following administration of 200 mg of fluconazole, the
mean percentage increase of AUC for levonorgestrel compared to
placebo was 25% (range: -12% to 82%) and the mean percentage
increase for ethinyl estradiol compared to placebo was 38% (range:
-11% to 101%). Both of these increases were statistically
significantly different from placebo.</p>
<p>A third study evaluated the potential interaction of once weekly
dosing of fluconazole 300 mg to 21 normal females taking an oral
contraceptive containing ethinyl estradiol and norethindrone. In
this placebo-controlled, double-blind, randomized, two-way
crossover study carried out over three cycles of oral contraceptive
treatment, fluconazole dosing resulted in small increases in the
mean AUCs of ethinyl estradiol and norethindrone compared to
similar placebo dosing. The mean AUCs of ethinyl estradiol and
norethindrone increased by 24% (95% C.I. range 18% to 31%) and 13%
(95% C.I. range 8% to 18%), respectively relative to placebo.
Fluconazole treatment did not cause a decrease in the ethinyl
estradiol AUC of any individual subject in this study compared to
placebo dosing. The individual AUC values of norethindrone
decreased very slightly (&lt; 5%) in 3 of the 21 subjects after
fluconazole treatment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_cb706826-e0fc-404e-baee-dee9186705c3" id=
"i4i_section_id_cb706826-e0fc-404e-baee-dee9186705c3"></a> <a name=
"section-2.4.2" id="section-2.4.2"></a>
<h3><span class="Bold"><span class=
"Italics">Cimetidine</span></span></h3>
<p class="First">Fluconazole 100 mg was administered as a single
oral dose alone and 2 hours after a single dose of cimetidine 400
mg to six healthy male volunteers. After the administration of
cimetidine, there was a significant decrease in fluconazole AUC and
C<span class="Sub">max</span>. There was a mean ± SD decrease in
fluconazole AUC of 13% ± 11% (range: -3.4% to -31%) and
C<span class="Sub">max</span> decreased 19% ± 14% (range: -5% to
-40%). However, the administration of cimetidine 600 mg to 900 mg
intravenously over a 4-hour period (from 1 hour before to 3 hours
after a single oral dose of fluconazole 200 mg) did not affect the
bioavailability or pharmacokinetics of fluconazole in 24 healthy
male volunteers.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_213f4465-ecfe-4c1d-b10a-4d9b50b7891a" id=
"i4i_section_id_213f4465-ecfe-4c1d-b10a-4d9b50b7891a"></a> <a name=
"section-2.4.3" id="section-2.4.3"></a>
<h3><span class="Bold"><span class=
"Italics">Antacid</span></span></h3>
<p class="First">Administration of Maalox<span class="Sup">®</span>
(20 mL) to 14 normal male volunteers immediately prior to a single
dose of fluconazole 100 mg had no effect on the absorption or
elimination of fluconazole.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b5763fc0-74d0-4e14-b97d-bd0ff4261d4c" id=
"i4i_section_id_b5763fc0-74d0-4e14-b97d-bd0ff4261d4c"></a> <a name=
"section-2.4.4" id="section-2.4.4"></a>
<h3><span class="Bold"><span class=
"Italics">Hydrochlorothiazide</span></span></h3>
<p class="First">Concomitant oral administration of 100 mg
fluconazole and 50 mg hydrochlorothiazide for 10 days in 13 normal
volunteers resulted in a significant increase in fluconazole AUC
and C<span class="Sub">max</span> compared to fluconazole given
alone. There was a mean ± SD increase in fluconazole AUC and
C<span class="Sub">max</span> of 45% ± 31% (range: 19% to 114%) and
43% ± 31% (range: 19% to 122%), respectively. These changes are
attributed to a mean ± SD reduction in renal clearance of 30% ± 12%
(range: -10% to -50%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_aa5e89d2-9786-4673-b7fa-7d90f81257be" id=
"i4i_section_id_aa5e89d2-9786-4673-b7fa-7d90f81257be"></a> <a name=
"section-2.4.5" id="section-2.4.5"></a>
<h3><span class="Bold"><span class=
"Italics">Rifampin</span></span></h3>
<p class="First">Administration of a single oral 200 mg dose of
fluconazole after 15 days of rifampin administered as 600 mg daily
in eight healthy male volunteers resulted in a significant decrease
in fluconazole AUC and a significant increase in apparent oral
clearance of fluconazole. There was a mean ± SD reduction in
fluconazole AUC of 23% ± 9% (range: -13% to -42%). Apparent oral
clearance of fluconazole increased 32% ± 17% (range: 16% to 72%).
Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9
hours. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b236bfbc-7705-4dba-b2f9-4b0b59e52846" id=
"i4i_section_id_b236bfbc-7705-4dba-b2f9-4b0b59e52846"></a> <a name=
"section-2.4.6" id="section-2.4.6"></a>
<h3><span class="Bold"><span class=
"Italics">Warfarin</span></span></h3>
<p class="First">There was a significant increase in prothrombin
time response (area under the prothrombin time-time curve)
following a single dose of warfarin (15 mg) administered to 13
normal male volunteers following oral fluconazole 200 mg
administered daily for 14 days as compared to the administration of
warfarin alone. There was a mean ± SD increase in the prothrombin
time response (area under the prothrombin time-time curve) of 7% ±
4% (range: -2% to 13%). (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)
Mean is based on data from 12 subjects as one of 13 subjects
experienced a 2-fold increase in his prothrombin time response.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_159f7bc8-a4d9-4089-864d-464539c65620" id=
"i4i_section_id_159f7bc8-a4d9-4089-864d-464539c65620"></a> <a name=
"section-2.4.7" id="section-2.4.7"></a>
<h3><span class="Bold"><span class=
"Italics">Phenytoin</span></span></h3>
<p class="First">Phenytoin AUC was determined after 4 days of
phenytoin dosing (200 mg daily, orally for 3 days followed by 250
mg intravenously for one dose) both with and without the
administration of fluconazole (oral fluconazole 200 mg daily for 16
days) in ten normal male volunteers. There was a significant
increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC
was 88% ± 68% (range: 16% to 247%). The absolute magnitude of this
interaction is unknown because of the intrinsically nonlinear
disposition of phenytoin. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6b71ee24-144a-4907-930c-a9ff1f43e1e2" id=
"i4i_section_id_6b71ee24-144a-4907-930c-a9ff1f43e1e2"></a> <a name=
"section-2.4.8" id="section-2.4.8"></a>
<h3><span class="Bold"><span class=
"Italics">Cyclosporine</span></span></h3>
<p class="First">Cyclosporine AUC and C<span class="Sub">max</span>
were determined before and after the administration of fluconazole
200 mg daily for 14 days in eight renal transplant patients who had
been on cyclosporine therapy for at least 6 months and on a stable
cyclosporine dose for at least 6 weeks. There was a significant
increase in cyclosporine AUC, C<span class="Sub">max</span>,
C<span class="Sub">min</span> (24-hour concentration), and a
significant reduction in apparent oral clearance following the
administration of fluconazole. The mean ± SD increase in AUC was
92% ± 43% (range: 18% to 147%). The C<span class="Sub">max</span>
increased 60% ± 48% (range: -5% to 133%). The C<span class=
"Sub">min</span> increased 157% ± 96% (range: 33% to 360%). The
apparent oral clearance decreased 45% ± 15% (range: -15% to -60%).
(See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_53cd8ba4-b949-4fb2-8c9c-f43d677f73eb" id=
"i4i_section_id_53cd8ba4-b949-4fb2-8c9c-f43d677f73eb"></a> <a name=
"section-2.4.9" id="section-2.4.9"></a>
<h3><span class="Bold"><span class=
"Italics">Zidovudine</span></span></h3>
<p class="First">Plasma zidovudine concentrations were determined
on two occasions (before and following fluconazole 200 mg daily for
15 days) in 13 volunteers with AIDS or ARC who were on a stable
zidovudine dose for at least 2 weeks. There was a significant
increase in zidovudine AUC following the administration of
fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range:
-27% to 104%). The metabolite, GZDV, to parent drug ratio
significantly decreased after the administration of fluconazole,
from 7.6 ± 3.6 to 5.7 ± 2.2.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3444e59b-5650-4b94-8be1-95628004655b" id=
"i4i_section_id_3444e59b-5650-4b94-8be1-95628004655b"></a> <a name=
"section-2.4.10" id="section-2.4.10"></a>
<h3><span class="Bold"><span class=
"Italics">Theophylline</span></span></h3>
<p class="First">The pharmacokinetics of theophylline were
determined from a single intravenous dose of aminophylline (6
mg/kg) before and after the oral administration of fluconazole 200
mg daily for 14 days in 16 normal male volunteers. There were
significant increases in theophylline AUC, C<span class=
"Sub">max</span> and half-life with a corresponding decrease in
clearance. The mean ± SD theophylline AUC increased 21% ± 16%
(range: -5% to 48%). The C<span class="Sub">max</span> increased
13% ± 17% (range: -13% to 40%). Theophylline clearance decreased
16% ± 11% (range: -32% to 5%). The half-life of theophylline
increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_18034860-7382-4356-9bf2-77adba9bfb5d" id=
"i4i_section_id_18034860-7382-4356-9bf2-77adba9bfb5d"></a> <a name=
"section-2.4.11" id="section-2.4.11"></a>
<h3><span class="Bold"><span class=
"Italics">Terfenadine</span></span></h3>
<p class="First">Six healthy volunteers received terfenadine 60 mg
BID for 15 days. Fluconazole 200 mg was administered daily from
days 9 through 15. Fluconazole did not affect terfenadine plasma
concentrations. Terfenadine acid metabolite AUC increased 36% ± 36%
(range: 7% to 102%) from day 8 to day 15 with the concomitant
administration of fluconazole. There was no change in cardiac
repolarization as measured by Holter QTc intervals. Another study
at a 400 mg and 800 mg daily dose of fluconazole demonstrated that
fluconazole taken in doses of 400 mg per day or greater
significantly increases plasma levels of terfenadine when taken
concomitantly. (See <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>
and <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_02da1bc6-380c-4d84-ae68-75a9ae0926e1" id=
"ID_02da1bc6-380c-4d84-ae68-75a9ae0926e1"></a> <a name=
"section-2.4.12" id="section-2.4.12"></a>
<h3><span class="Bold"><span class=
"Italics">Quinidine</span></span></h3>
<p class="First">Although not studied <span class="Italics">in
vitro</span> or <span class="Italics">in vivo</span>, concomitant
administration of fluconazole with quinidine may result in
inhibition of quinidine metabolism. Use of quinidine has been
associated with QT prolongation and rare occurrences of torsade de
pointes. Coadministration of fluconazole and quinidine is
contraindicated. (See <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>
and <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_a8e6bf22-fc3e-4b4c-b103-677f78f6dc9a" id=
"i4i_section_id_a8e6bf22-fc3e-4b4c-b103-677f78f6dc9a"></a> <a name=
"section-2.4.13" id="section-2.4.13"></a>
<h3><span class="Bold"><span class="Italics">Oral
Hypoglycemics</span></span></h3>
<p class="First">The effects of fluconazole on the pharmacokinetics
of the sulfonylurea oral hypoglycemic agents tolbutamide,
glipizide, and glyburide were evaluated in three placebo-controlled
studies in normal volunteers. All subjects received the
sulfonylurea alone as a single dose and again as a single dose
following the administration of fluconazole 100 mg daily for 7
days. In these three studies, 22/46 (47.8%) of fluconazole treated
patients and 9/22 (40.1%) of placebo-treated patients experienced
symptoms consistent with hypoglycemia. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5106296a-7267-408a-b878-375646ecfc91" id=
"i4i_section_id_5106296a-7267-408a-b878-375646ecfc91"></a> <a name=
"section-2.4.13.1" id="section-2.4.13.1"></a>
<h4>Tolbutamide</h4>
<p class="First">In 13 normal male volunteers, there was
significant increase in tolbutamide (500 mg single dose) AUC and
C<span class="Sub">max</span> following the administration of
fluconazole. There was a mean ± SD increase in tolbutamide AUC of
26% ± 9% (range: 12% to 39%). Tolbutamide C<span class=
"Sub">max</span> increased 11% ± 9% (range: -6% to 27%). (See
<a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_916f967d-2dd3-4154-aeb7-924fe10f03ce" id=
"i4i_section_id_916f967d-2dd3-4154-aeb7-924fe10f03ce"></a> <a name=
"section-2.4.13.2" id="section-2.4.13.2"></a>
<h4>Glipizide</h4>
<p class="First">The AUC and C<span class="Sub">max</span> of
glipizide (2.5 mg single dose) were significantly increased
following the administration of fluconazole in 13 normal male
volunteers. There was a mean ± SD increase in AUC of 49% ± 13%
(range: 27% to 73%) and an increase in C<span class=
"Sub">max</span> of 19% ± 23% (range: -11% to 79%). (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_0224b04c-45d2-47e6-b29c-79e185f7899b" id=
"i4i_section_id_0224b04c-45d2-47e6-b29c-79e185f7899b"></a> <a name=
"section-2.4.13.3" id="section-2.4.13.3"></a>
<h4>Glyburide</h4>
<p class="First">The AUC and C<span class="Sub">max</span> of
glyburide (5 mg single dose) were significantly increased following
the administration of fluconazole in 20 normal male volunteers.
There was a mean ± SD increase in AUC of 44% ± 29% (range: -13% to
115%) and C<span class="Sub">max</span> increased 19% ± 19% (range:
-23% to 62%). Five subjects required oral glucose following the
ingestion of glyburide after 7 days of fluconazole administration.
(See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_f443e638-7bc6-4142-a4f1-9769a938189a" id=
"i4i_section_id_f443e638-7bc6-4142-a4f1-9769a938189a"></a> <a name=
"section-2.4.14" id="section-2.4.14"></a>
<h3><span class="Bold"><span class=
"Italics">Rifabutin</span></span></h3>
<p class="First">There have been published reports that an
interaction exists when fluconazole is administered concomitantly
with rifabutin, leading to increased serum levels of rifabutin.
(See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c8a6bc62-6e7a-4b87-9184-000b9b816bab" id=
"i4i_section_id_c8a6bc62-6e7a-4b87-9184-000b9b816bab"></a> <a name=
"section-2.4.15" id="section-2.4.15"></a>
<h3><span class="Bold"><span class=
"Italics">Tacrolimus</span></span></h3>
<p class="First">There have been published reports that an
interaction exists when fluconazole is administered concomitantly
with tacrolimus, leading to increased serum levels of tacrolimus.
(See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b0c49ce9-4f20-4a4a-a0ad-b44c83dd9109" id=
"i4i_section_id_b0c49ce9-4f20-4a4a-a0ad-b44c83dd9109"></a> <a name=
"section-2.4.16" id="section-2.4.16"></a>
<h3><span class="Bold"><span class=
"Italics">Cisapride</span></span></h3>
<p class="First">A placebo-controlled, randomized, multiple-dose
study examined the potential interaction of fluconazole with
cisapride. Two groups of ten normal subjects were administered
fluconazole 200 mg daily or placebo. Cisapride 20 mg four times
daily was started after 7 days of fluconazole or placebo dosing.
Following a single dose of fluconazole, there was a 101% increase
in the cisapride AUC and a 91% increase in the cisapride
C<span class="Sub">max</span>. Following multiple doses of
fluconazole, there was a 192% increase in the cisapride AUC and a
154% increase in the cisapride C<span class="Sub">max</span>.
Fluconazole significantly increased the QTc interval in subjects
receiving cisapride 20 mg four times daily for 5 days. (See
<a href="#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">
CONTRAINDICATIONS</a> and <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_e6eac062-00e8-46bf-8373-0ebcd319d40d" id=
"i4i_section_id_e6eac062-00e8-46bf-8373-0ebcd319d40d"></a> <a name=
"section-2.4.17" id="section-2.4.17"></a>
<h3><span class="Bold"><span class=
"Italics">Midazolam</span></span></h3>
<p class="First">The effect of fluconazole on the pharmacokinetics
and pharmacodynamics of midazolam was examined in a randomized,
cross-over study in 12 volunteers. In the study, subjects ingested
placebo or 400 mg fluconazole on Day 1 followed by 200 mg daily
from Day 2 to Day 6. In addition, a 7.5 mg dose of midazolam was
orally ingested on the first day, 0.05 mg/kg was administered
intravenously on the fourth day, and 7.5 mg orally on the sixth
day. Fluconazole reduced the clearance of IV midazolam by 51%. On
the first day of dosing, fluconazole increased the midazolam AUC
and C<span class="Sub">max</span> by 259% and 150%, respectively.
On the sixth day of dosing, fluconazole increased the midazolam AUC
and C<span class="Sub">max</span> by 259% and 74%, respectively.
The psychomotor effects of midazolam were significantly increased
after oral administration of midazolam but not significantly
affected following intravenous midazolam.</p>
<p>A second randomized, double-dummy, placebo-controlled,
cross-over study in three phases was performed to determine the
effect of route of administration of fluconazole on the interaction
between fluconazole and midazolam. In each phase the subjects were
given oral fluconazole 400 mg and intravenous saline; oral placebo
and intravenous fluconazole 400 mg; and oral placebo and IV saline.
An oral dose of 7.5 mg of midazolam was ingested after
fluconazole/placebo. The AUC and C<span class="Sub">max</span> of
midazolam were significantly higher after oral than IV
administration of fluconazole. Oral fluconazole increased the
midazolam AUC and C<span class="Sub">max</span> by 272% and 129%,
respectively. IV fluconazole increased the midazolam AUC and
C<span class="Sub">max</span> by 244% and 79%, respectively. Both
oral and IV fluconazole increased the pharmacodynamic effects of
midazolam. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_a155a7c5-f154-4490-ae10-e1d6b93709b9" id=
"i4i_section_id_a155a7c5-f154-4490-ae10-e1d6b93709b9"></a> <a name=
"section-2.4.18" id="section-2.4.18"></a>
<h3><span class="Bold"><span class=
"Italics">Azithromycin</span></span></h3>
<p class="First">An open-label, randomized, three-way crossover
study in 18 healthy subjects assessed the effect of a single 800 mg
oral dose of fluconazole on the pharmacokinetics of a single 1200
mg oral dose of azithromycin as well as the effects of azithromycin
on the pharmacokinetics of fluconazole. There was no significant
pharmacokinetic interaction between fluconazole and
azithromycin.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c1fdb0fb-5ac0-417d-8cc4-7a0ae68f9b21" id=
"i4i_section_id_c1fdb0fb-5ac0-417d-8cc4-7a0ae68f9b21"></a> <a name=
"section-2.4.19" id="section-2.4.19"></a>
<h3><span class="Bold"><span class=
"Italics">Voriconazole</span></span></h3>
<p class="First">Voriconazole is a substrate for both CYP2C9 and
CYP3A4 isoenzymes. Concurrent administration of oral voriconazole
(400 mg Q12h for 1 day, then 200 mg Q12h for 2.5 days) and oral
fluconazole (400 mg on day 1, then 200 mg Q24h for 4 days) to six
healthy male subjects resulted in an increase in C<span class=
"Sub">max</span> and AUC<span class="Sub">τ</span> of voriconazole
by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%,
128%), respectively. In a follow-on clinical study involving eight
healthy male subjects, reduced dosing and/or frequency of
voriconazole and fluconazole did not eliminate or diminish this
effect. Concomitant administration of voriconazole and fluconazole
at any dose is not recommended. Close monitoring for adverse events
related to voriconazole is recommended if voriconazole is used
sequentially after fluconazole, especially within 24 hours of the
last dose of fluconazole. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_119cf615-4d03-4873-8282-4b82d6b8be11" id=
"ID_119cf615-4d03-4873-8282-4b82d6b8be11"></a> <a name=
"section-2.4.20" id="section-2.4.20"></a>
<h3><span class="Bold"><span class=
"Italics">Tofacitinib</span></span></h3>
<p class="First">Coadministration of fluconazole (400 mg on Day 1
and 200 mg once daily for 6 days [Days 2 to 7]) and tofacitinib (30
mg single dose on Day 5) in healthy subjects resulted in increased
mean tofacitinib AUC and C<span class="Sub">max</span> values of
approximately 79% (90% CI: 64% to 96%) and 27% (90% CI: 12% to
44%), respectively, compared to administration of tofacitinib
alone. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c4c82d0d-9c1c-4cad-bdbd-04b3b1812b51" id=
"i4i_section_id_c4c82d0d-9c1c-4cad-bdbd-04b3b1812b51"></a> <a name=
"section-2.5" id="section-2.5"></a>
<h2>Microbiology</h2>
<div class="Section" data-sectioncode="43679-0"><a name=
"ID_9fcfb9d0-db24-4179-83a8-63f08d5fe457" id=
"ID_9fcfb9d0-db24-4179-83a8-63f08d5fe457"></a> <a name=
"section-2.5.1" id="section-2.5.1"></a>
<h3><span class="Bold"><span class="Italics">Mechanism of
Action</span></span></h3>
<p class="First">Fluconazole is a highly selective inhibitor of
fungal cytochrome P450 dependent enzyme lanosterol
14-α-demethylase. This enzyme functions to convert lanosterol to
ergosterol. The subsequent loss of normal sterols correlates with
the accumulation of 14-α-methyl sterols in fungi and may be
responsible for the fungistatic activity of fluconazole. Mammalian
cell demethylation is much less sensitive to fluconazole
inhibition.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_2b35272c-8228-478b-bfe6-48871e7040e6" id=
"ID_2b35272c-8228-478b-bfe6-48871e7040e6"></a> <a name=
"section-2.6" id="section-2.6"></a>
<h2>Drug Resistance</h2>
<p class="First">Fluconazole resistance may arise from a
modification in the quality or quantity of the target enzyme
(lanosterol 14-α-demethylase), reduced access to the drug target,
or some combination of these mechanisms.</p>
<p>Point mutations in the gene (<span class="Italics">ERG11</span>)
encoding for the target enzyme lead to an altered target with
decreased affinity for azoles. Overexpression of <span class=
"Italics">ERG11</span> results in the production of high
concentrations of the target enzyme, creating the need for higher
intracellular drug concentrations to inhibit all of the enzyme
molecules in the cell.</p>
<p>The second major mechanism of drug resistance involves active
efflux of fluconazole out of the cell through the activation of two
types of multidrug efflux transporters; the major facilitators
(encoded by <span class="Italics">MDR</span> genes) and those of
the ATP-binding cassette superfamily (encoded by <span class=
"Italics">CDR</span> genes). Upregulation of the <span class=
"Italics">MDR</span> gene leads to fluconazole resistance, whereas,
upregulation of <span class="Italics">CDR</span> genes may lead to
resistance to multiple azoles.</p>
<p>Resistance in <span class="Italics">Candida glabrata</span>
usually includes upregulation of <span class="Italics">CDR</span>
genes resulting in resistance to multiple azoles. For an isolate
where the MIC is categorized as Intermediate (16 to 32 mcg/mL), the
highest fluconazole dose is recommended.</p>
<p><span class="Italics">Candida krusei</span> should be considered
to be resistant to fluconazole. Resistance in<br>
<span class="Italics">C. krusei</span> appears to be mediated by
reduced sensitivity of the target enzyme to inhibition by the
agent.</p>
<p>There have been reports of cases of superinfection with
<span class="Italics">Candida</span> species other than<br>
<span class="Italics">C. albicans,</span> which are often
inherently not susceptible to fluconazole (e.g., <span class=
"Italics">Candida krusei</span>). Such cases may require
alternative antifungal therapy.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_8d18215b-1fc9-4c60-87f5-6a0c269b8a28" id=
"i4i_section_id_8d18215b-1fc9-4c60-87f5-6a0c269b8a28"></a> <a name=
"section-2.7" id="section-2.7"></a>
<h2>Activity <span class="Italics">In Vitro</span> and In Clinical
Infections</h2>
<p class="First">Fluconazole has been shown to be active against
most strains of the following microorganisms <span class=
"Bold">both <span class="Italics">in vitro</span> and in clinical
infections.</span></p>
<p><span class="Italics">Candida albicans</span><br>
<span class="Italics">Candida glabrata</span> (Many strains are
intermediately susceptible)*<br>
<span class="Italics">Candida parapsilosis</span><br>
<span class="Italics">Candida tropicalis</span><br>
<span class="Italics">Cryptococcus neoformans</span></p>
<p><span class="Italics">* In a majority of the studies,
fluconazole MIC<span class="Sub">90</span> values against C.
glabrata were above the susceptible breakpoint (≥ 16 mcg/mL).
Resistance in Candida glabrata usually includes upregulation of CDR
genes resulting in resistance to multiple azoles. For an isolate
where the MIC is categorized as intermediate (16 to 32 mcg/mL, see
Table 1), the highest dose is recommended. (See <a href=
"#i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14">DOSAGE
AND ADMINISTRATION</a>.) For resistant isolates, alternative
therapy is recommended.</span></p>
<p>The following <span class="Italics">in vitro</span> data are
available, <span class="Bold">but their clinical significance is
unknown.</span></p>
<p>Fluconazole exhibits <span class="Italics">in vitro</span>
minimum inhibitory concentrations (MIC values) of 8 mcg/mL or less
against most (≥ 90%) strains of the following microorganisms,
however, the safety and effectiveness of fluconazole in treating
clinical infections due to these microorganisms have not been
established in adequate and well-controlled trials.</p>
<p><span class="Italics">Candida dubliniensis</span><br>
<span class="Italics">Candida guilliermondii</span><br>
<span class="Italics">Candida kefyr</span><br>
<span class="Italics">Candida lusitaniae</span></p>
<p><span class="Italics">Candida krusei</span> should be considered
to be resistant to fluconazole. Resistance in <span class=
"Italics">C. krusei</span> appears to be mediated by reduced
sensitivity of the target enzyme to inhibition by the agent.</p>
<p>There have been reports of cases of superinfection with
<span class="Italics">Candida</span> species other than
<span class="Italics">C. albicans,</span> which are often
inherently not susceptible to fluconazole (e.g., <span class=
"Italics">Candida krusei</span>). Such cases may require
alternative antifungal therapy.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_fbc2dc27-7051-47de-8431-e502149fcd9f" id=
"i4i_section_id_fbc2dc27-7051-47de-8431-e502149fcd9f"></a> <a name=
"section-2.8" id="section-2.8"></a>
<h2>Susceptibility Testing Methods</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_8d690392-a207-4bab-9fe7-a7c937d4442c" id=
"i4i_section_id_8d690392-a207-4bab-9fe7-a7c937d4442c"></a> <a name=
"section-2.8.1" id="section-2.8.1"></a>
<h3><span class="Bold"><span class="Italics">Cryptococcus
Neoformans and Filamentous Fungi</span></span></h3>
<p class="First">No interpretive criteria have been established for
<span class="Italics">Cryptococcus neoformans</span> and
filamentous fungi<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ef64bb2b-5013-45bd-a600-a1d042d3e642" id=
"i4i_section_id_ef64bb2b-5013-45bd-a600-a1d042d3e642"></a> <a name=
"section-2.8.2" id="section-2.8.2"></a>
<h3><span class="Bold"><span class="Italics">Candida
Species</span></span></h3>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_19e6fb44-a777-4091-a363-eb4153590e47" id=
"ID_19e6fb44-a777-4091-a363-eb4153590e47"></a> <a name=
"section-2.8.2.1" id="section-2.8.2.1"></a>
<h4>Broth Dilution Techniques</h4>
<p class="First">Quantitative methods are used to determine
antifungal minimum inhibitory concentrations (MICs). These MICs
provide estimates of the susceptibility of <span class=
"Italics">Candida</span> spp. to antifungal agents. MICs should be
determined using a standardized procedure. Standardized procedures
are based on a dilution method (broth)<span class="Sup">1</span>
with standardized inoculum concentrations of fluconazole powder.
The MIC values should be interpreted according to the criteria
provided in Table 1.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_e302a259-3043-4513-9f92-1d55e8504dbb" id=
"i4i_section_id_e302a259-3043-4513-9f92-1d55e8504dbb"></a> <a name=
"section-2.8.2.2" id="section-2.8.2.2"></a>
<h4>Diffusion Techniques</h4>
<p class="First">Qualitative methods that require measurement of
zone diameters also provide reproducible estimates of the
susceptibility of <span class="Italics">Candida</span> spp. to an
antifungal agent. One such standardized procedure<span class=
"Sup">2</span> requires the use of standardized inoculum
concentrations. This procedure uses paper disks impregnated with 25
mcg of fluconazole to test the susceptibility of yeasts to
fluconazole. Disk diffusion interpretive criteria are also provided
in Table 1.</p>
<a name="_RefID0EL5AE" id="_RefID0EL5AE"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 1: Susceptibility Interpretive Criteria for
Fluconazole against Candida species</span></caption>
<colgroup>
<col width="18%">
<col width="13%">
<col width="14%">
<col width="11%">
<col width="13%">
<col width="14%">
<col width="11%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="7">
<dl class="Footnote">
<dt><a href="#footnote-reference-3" name="footnote-3" id=
"footnote-3">*</a></dt>
<dd>The intermediate category is sometimes called Susceptible-Dose
Dependent (SDD) and both categories are equivalent for
fluconazole.</dd>
<dt><a href="#footnote-reference-4" name="footnote-4" id=
"footnote-4">†</a></dt>
<dd>Isolates of <span class="Italics">C. krusei</span> are assumed
to be intrinsically resistant to fluconazole and their MICs and/or
zone diameters should not be interpreted using this scale.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="top">
<p class="First"><span class="Bold">Broth Dilution at 48 hours<br>
(MIC in mcg/mL)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="top">
<p class="First"><span class="Bold">Disk Diffusion at 24 hours<br>
(Zone Diameters in mm)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Antifungal agent</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Susceptible<br>
(S)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Intermediate<br>
(I)<a class="Sup" href="#footnote-3" name="footnote-reference-3"
id="footnote-reference-3">*</a></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Resistant<br>
(R)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Susceptible<br>
(S)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Intermediate<br>
(I)<a class="Sup" href="#footnote-3">*</a></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Resistant<br>
(R)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Fluconazole<a class="Sup" href="#footnote-4" name=
"footnote-reference-4" id="footnote-reference-4">†</a></p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">≤ 8.0</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">16 to 32</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">≥ 64</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">≥ 19</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">15 to 18</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">≤ 14</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>A report of <span class="Italics">Susceptible</span> (S)
indicates that the antimicrobial drug is likely to inhibit growth
of the microorganism if the antimicrobial drug reaches the
concentration usually achievable at the site of infection.</p>
<p>A report of <span class="Italics">Intermediate</span> (I)
indicates that an infection due to the isolate may be appropriately
treated in body sites where the drugs are physiologically
concentrated or when a high dosage of drug is used.</p>
<p>A report of <span class="Italics">Resistant</span> (R) indicates
that the antimicrobial is not likely to inhibit growth of the
pathogen if the antimicrobial drug reaches the concentrations
usually achievable at the infection site; other therapy should be
selected.</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_e7d632ca-fb2d-4500-afb4-a3b29bfea927" id=
"i4i_section_id_e7d632ca-fb2d-4500-afb4-a3b29bfea927"></a> <a name=
"section-2.9" id="section-2.9"></a>
<h2>Quality Control</h2>
<p class="First">Standardized susceptibility test procedures
require the use of quality control organisms to control the
technical aspects of the test procedures. Standardized fluconazole
powder and 25 mcg disks should provide the following range of
values noted in Table 2. NOTE: Quality control microorganisms are
specific strains of organisms with intrinsic biological properties
relating to resistance mechanisms and their genetic expression
within fungi; the specific strains used for microbiological control
are not clinically significant.</p>
<a name="_Refid_8f709de2-fbe9-45fd-b6ac-4f2fb785f" id=
"_Refid_8f709de2-fbe9-45fd-b6ac-4f2fb785f"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 2: Acceptable Quality Control Ranges for
Fluconazole to be Used in Validation of Susceptibility Test
Results</span></caption>
<colgroup>
<col width="34%">
<col width="19%">
<col width="19%">
<col width="24%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="4">
<dl class="Footnote">
<dt><a href="#footnote-reference-5" name="footnote-5" id=
"footnote-5">*</a></dt>
<dd>Quality control ranges have not been established for this
strain/antifungal agent combination due to their extensive
interlaboratory variation during initial quality control
studies.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"middle">
<p class="First"><span class="Bold">QC Strain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold">Macrodilution<br>
(MIC in mcg/mL)<br>
@ 48 hours</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold">Microdilution<br>
(MIC in mcg/mL)<br>
@ 48 hours</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold">Disk Diffusion<br>
(Zone Diameter in mm)<br>
@ 24 hours</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Candida parapsilosis ATCC 22019</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2.0 to 8.0</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1.0 to 4.0</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">22 to 33</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Candida krusei ATCC 6258</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">16 to 64</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">16 to 128</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">---<a class="Sup" href="#footnote-5" name=
"footnote-reference-5" id="footnote-reference-5">*</a></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Candida albicans ATCC 90028</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">---<a class="Sup" href="#footnote-5">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">---<a class="Sup" href="#footnote-5">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">28 to 39</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Candida tropicalis ATCC 750</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">---<a class="Sup" href="#footnote-5">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">---<a class="Sup" href="#footnote-5">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">26 to 37</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name=
"i4i_indications_id_f55f7392-07e8-4a22-bcf3-409cdf06518a" id=
"i4i_indications_id_f55f7392-07e8-4a22-bcf3-409cdf06518a"></a>
<a name="section-3" id="section-3"></a>
<p class="First">Fluconazole tablets are indicated for the
treatment of:</p>
<dl>
<dt>1.</dt>
<dd>Vaginal candidiasis (vaginal yeast infections due to
<span class="Italics">Candida</span>).</dd>
<dt>2.</dt>
<dd>Oropharyngeal and esophageal candidiasis. In open
noncomparative studies of relatively small numbers of patients,
fluconazole tablets were also effective for the treatment of
<span class="Italics">Candida</span> urinary tract infections,
peritonitis, and systemic <span class="Italics">Candida</span>
infections including candidemia, disseminated candidiasis, and
pneumonia.</dd>
<dt>3.</dt>
<dd>Cryptococcal meningitis. Before prescribing fluconazole tablets
for AIDS patients with cryptococcal meningitis, please see <a href=
"#i4i_clinical_studies_id_ebe54b2c-2c38-4eeb-91de-ca3a681172e2">CLINICAL
STUDIES</a> section. Studies comparing fluconazole tablets to
amphotericin B in non-HIV infected patients have not been
conducted.</dd>
</dl>
<p>Prophylaxis. Fluconazole tablets are also indicated to decrease
the incidence of candidiasis in patients undergoing bone marrow
transplantation who receive cytotoxic chemotherapy and/or radiation
therapy.</p>
<p>Specimens for fungal culture and other relevant laboratory
studies (serology, histopathology) should be obtained prior to
therapy to isolate and identify causative organisms. Therapy may be
instituted before the results of the cultures and other laboratory
studies are known; however, once these results become available,
anti-infective therapy should be adjusted accordingly.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name=
"i4i_clinical_studies_id_ebe54b2c-2c38-4eeb-91de-ca3a681172e2" id=
"i4i_clinical_studies_id_ebe54b2c-2c38-4eeb-91de-ca3a681172e2"></a>
<a name="section-4" id="section-4"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_33567db8-0e26-4298-b3c5-ac8bce860342" id=
"i4i_section_id_33567db8-0e26-4298-b3c5-ac8bce860342"></a> <a name=
"section-4.1" id="section-4.1"></a>
<h2>Cryptococcal Meningitis</h2>
<p class="First">In a multicenter study comparing fluconazole (200
mg/day) to amphotericin B (0.3 mg/kg/day) for treatment of
cryptococcal meningitis in patients with AIDS, a multivariate
analysis revealed three pretreatment factors that predicted death
during the course of therapy: abnormal mental status, cerebrospinal
fluid cryptococcal antigen titer greater than 1:1024, and
cerebrospinal fluid white blood cell count of less than 20
cells/mm<span class="Sup">3</span>. Mortality among high risk
patients was 33% and 40% for amphotericin B and fluconazole
patients, respectively (p = 0.58), with overall deaths 14% (9 of 63
subjects) and 18% (24 of 131 subjects) for the two arms of the
study (p = 0.48). Optimal doses and regimens for patients with
acute cryptococcal meningitis and at high risk for treatment
failure remain to be determined. (Saag, <span class="Italics">et
al.</span> N Engl J Med 1992; 326:83-9.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_0e42a3f4-6e9a-4e22-907c-fef1517267c8" id=
"i4i_section_id_0e42a3f4-6e9a-4e22-907c-fef1517267c8"></a> <a name=
"section-4.2" id="section-4.2"></a>
<h2>Vaginal Candidiasis</h2>
<p class="First">Two adequate and well-controlled studies were
conducted in the U.S. using the 150 mg tablet. In both, the results
of the fluconazole regimen were comparable to the control regimen
(clotrimazole or miconazole intravaginally for 7 days) both
clinically and statistically at the one month post-treatment
evaluation.</p>
<p>The therapeutic cure rate, defined as a complete resolution of
signs and symptoms of vaginal candidiasis (clinical cure), along
with a negative KOH examination and negative culture for
<span class="Italics">Candida</span> (microbiologic eradication),
was 55% in both the fluconazole group and the vaginal products
group.</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="29%">
<col width="32%">
<col width="31%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class=
"Underline">Fluconazole PO 150 mg Tablet</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Underline">Vaginal
Product qhs x 7 Days</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Enrolled</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">448</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">422</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Evaluable at Late Follow-up</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">347 (77%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">327 (77%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Clinical cure</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">239/347 (69%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">235/327 (72%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Mycologic eradication</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">213/347 (61%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">196/327 (60%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Therapeutic cure</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">190/347 (55%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">179/327 (55%)</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>Approximately three-fourths of the enrolled patients had acute
vaginitis (&lt; 4 episodes/12 months) and achieved 80% clinical
cure, 67% mycologic eradication, and 59% therapeutic cure when
treated with a 150 mg fluconazole tablet administered orally. These
rates were comparable to control products. The remaining one-fourth
of enrolled patients had recurrent vaginitis (≥ 4 episodes/12
months) and achieved 57% clinical cure, 47% mycologic eradication,
and 40% therapeutic cure. The numbers are too small to make
meaningful clinical or statistical comparisons with vaginal
products in the treatment of patients with recurrent vaginitis.</p>
<p>Substantially more gastrointestinal events were reported in the
fluconazole group compared to the vaginal product group. Most of
the events were mild to moderate. Because fluconazole was given as
a single dose, no discontinuations occurred.<br></p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="25%">
<col width="18%">
<col width="19%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class=
"Underline">Parameter</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class=
"Underline">Fluconazole PO</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Underline">Vaginal
Products</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Evaluable patients</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">448</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">422</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">With any adverse event</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">141 (31%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">112 (27%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nervous System</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">90 (20%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">69 (16%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Gastrointestinal</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">73 (16%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">18 (4%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">With drug-related event</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">117 (26%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">67 (16%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nervous System</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">61 (14%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">29 (7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Headache</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">58 (13%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">28 (7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Gastrointestinal</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">68 (15%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">13 (3%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Abdominal pain</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">25 (6%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">7 (2%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nausea</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">30 (7%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">3 (1%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Diarrhea</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">12 (3%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">2 (&lt;1%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Application site event</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">0 (0%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">19 (5%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Taste Perversion</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">6 (1%)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">0 (0%)</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_8d2e5150-a364-4388-ac57-bb7fb62fa050" id=
"i4i_section_id_8d2e5150-a364-4388-ac57-bb7fb62fa050"></a> <a name=
"section-4.3" id="section-4.3"></a>
<h2>Pediatric Studies</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_f564a6b5-325e-4e0f-b48e-e484a820ee53" id=
"i4i_section_id_f564a6b5-325e-4e0f-b48e-e484a820ee53"></a> <a name=
"section-4.3.1" id="section-4.3.1"></a>
<h3><span class="Bold"><span class="Italics">Oropharyngeal
Candidiasis</span></span></h3>
<p class="First">An open-label, comparative study of the efficacy
and safety of fluconazole (2 to 3 mg/kg/day) and oral nystatin
(400,000 I.U. four times daily) in immunocompromised children with
oropharyngeal candidiasis was conducted. Clinical and mycological
response rates were higher in the children treated with
fluconazole.</p>
<p>Clinical cure at the end of treatment was reported for 86% of
fluconazole-treated patients compared to 46% of nystatin treated
patients. Mycologically, 76% of fluconazole-treated patients had
the infecting organism eradicated compared to 11% for nystatin
treated patients.</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="25%">
<col width="14%">
<col width="14%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-6" name="footnote-6" id=
"footnote-6">*</a></dt>
<dd>Subjects without follow-up cultures for any reason were
considered nonevaluable for mycological response.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class=
"Underline">Fluconazole</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class=
"Underline">Nystatin</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Enrolled</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">96</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">90</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Clinical Cure</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">76/88 (86%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">36/78 (46%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Mycological eradication<a class="Sup" href=
"#footnote-6" name="footnote-reference-6" id=
"footnote-reference-6">*</a></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">55/72 (76%)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">6/54 (11%)</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>The proportion of patients with clinical relapse 2 weeks after
the end of treatment was 14% for subjects receiving fluconazole and
16% for subjects receiving nystatin. At 4 weeks after the end of
treatment, the percentages of patients with clinical relapse were
22% for fluconazole and 23% for nystatin.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name=
"i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d" id=
"i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d"></a>
<a name="section-5" id="section-5"></a>
<p class="First">Fluconazole tablets are contraindicated in
patients who have shown hypersensitivity to fluconazole or to any
of its excipients. There is no information regarding
cross-hypersensitivity between fluconazole and other azole
antifungal agents. Caution should be used in prescribing
fluconazole to patients with hypersensitivity to other azoles.
Coadministration of terfenadine is contraindicated in patients
receiving fluconazole at multiple doses of 400 mg or higher based
upon results of a multiple dose interaction study. Coadministration
of other drugs known to prolong the QT interval and which are
metabolized via the enzyme CYP3A4 such as cisapride, astemizole,
erythromycin, pimozide, and quinidine are contraindicated in
patients receiving fluconazole. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a> and <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">WARNINGS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34071-1"><a name=
"i4i_warnings_id_72427026-310b-4b8e-8c83-c7159e5236c6" id=
"i4i_warnings_id_72427026-310b-4b8e-8c83-c7159e5236c6"></a>
<a name="section-6" id="section-6"></a>
<p class="First"><span class="Bold">(1) Hepatic Injury: Fluconazole
should be administered with caution to patients with liver
dysfunction. Fluconazole has been associated with rare cases of
serious hepatic toxicity, including fatalities primarily in
patients with serious underlying medical conditions. In cases of
fluconazole-associated hepatotoxicity, no obvious relationship to
total daily dose, duration of therapy, sex, or age of the patient
has been observed. Fluconazole hepatotoxicity has usually, but not
always, been reversible on discontinuation of therapy. Patients who
develop abnormal liver function tests during fluconazole therapy
should be monitored for the development of more severe hepatic
injury. Fluconazole should be discontinued if clinical signs and
symptoms consistent with liver disease develop that may be
attributable to fluconazole.</span></p>
<p>(2) Anaphylaxis: In rare cases, anaphylaxis has been
reported.</p>
<p>(3) Dermatologic: Exfoliative skin disorders during treatment
with fluconazole have been reported. Fatal outcomes have been
reported in patients with serious underlying diseases. Patients
with deep seated fungal infections who develop rashes during
treatment with fluconazole should be monitored closely and the drug
discontinued if lesions progress. Fluconazole should be
discontinued in patients treated for superficial fungal infection
who develop a rash that may be attributed to fluconazole.</p>
<p>(4) Use in Pregnancy: There are no adequate and well-controlled
studies of fluconazole in pregnant women. Available human data do
not suggest an increased risk of congenital anomalies following a
single maternal dose of 150 mg. A few published case reports
describe a rare pattern of distinct congenital anomalies in infants
exposed <span class="Italics">in utero</span> to high dose maternal
fluconazole (400 to 800 mg/day) during most or all of the first
trimester. These reported anomalies are similar to those seen in
animal studies. If this drug is used during pregnancy or if the
patient becomes pregnant while taking the drug, the patient should
be informed of the potential hazard to the fetus. (See <a href=
"#i4i_section_id_56083f1a-dee2-427f-843e-bf3d80cd7eef">PRECAUTIONS:
Pregnancy</a>.)</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name=
"i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990" id=
"i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990"></a>
<a name="section-7" id="section-7"></a>
<div class="Section" data-sectioncode="34072-9"><a name=
"i4i_precautions_general_id_9edf3e85-ac6d-44e1-befe-89670893dd22"
id=
"i4i_precautions_general_id_9edf3e85-ac6d-44e1-befe-89670893dd22"></a>
<a name="section-7.1" id="section-7.1"></a>
<h2>General</h2>
<p class="First">Some azoles, including fluconazole, have been
associated with prolongation of the QT interval on the
electrocardiogram. During post-marketing surveillance, there have
been rare cases of QT prolongation and torsade de pointes in
patients taking fluconazole. Most of these reports involved
seriously ill patients with multiple confounding risk factors, such
as structural heart disease, electrolyte abnormalities, and
concomitant medications that may have been contributory.</p>
<p>Fluconazole should be administered with caution to patients with
these potentially proarrhythmic conditions.</p>
<p>Concomitant use of fluconazole and erythromycin has the
potential to increase the risk of cardiotoxicity (prolonged QT
interval, torsade de pointes) and consequently sudden heart death.
This combination should be avoided.</p>
<p>Fluconazole should be administered with caution to patients with
renal dysfunction.</p>
<p>Fluconazole is a potent CYP2C9 inhibitor and a moderate CYP3A4
inhibitor. Fluconazole-treated patients who are concomitantly
treated with drugs with a narrow therapeutic window metabolized
through CYP2C9 and CYP3A4 should be monitored.</p>
<p>When driving vehicles or operating machines, it should be taken
into account that occasionally dizziness or seizures may occur.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3ee27035-c811-4dc6-b716-cd58785c6217" id=
"i4i_section_id_3ee27035-c811-4dc6-b716-cd58785c6217"></a> <a name=
"section-7.1.1" id="section-7.1.1"></a>
<h3><span class="Bold"><span class="Italics">Single
Dose</span></span></h3>
<p class="First">The convenience and efficacy of the single dose
oral tablet of fluconazole regimen for the treatment of vaginal
yeast infections should be weighed against the acceptability of a
higher incidence of drug-related adverse events with fluconazole
(26%) versus intravaginal agents (16%) in U.S. comparative clinical
studies. (See <a href=
"#i4i_adverse_effects_id_52cbbd8c-9715-416b-ad57-d207d8e7c2e6">ADVERSE
REACTIONS</a> and <a href=
"#i4i_clinical_studies_id_ebe54b2c-2c38-4eeb-91de-ca3a681172e2">CLINICAL
STUDIES</a>.)</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_1f230b42-a077-4e49-ae17-acb74b5620a1" id=
"i4i_section_id_1f230b42-a077-4e49-ae17-acb74b5620a1"></a> <a name=
"section-7.2" id="section-7.2"></a>
<h2>Drug Interactions</h2>
<p class="First">(See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a> and <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>.)
Fluconazole is a potent inhibitor of cytochrome P450 (CYP)
isoenzyme 2C9 and 2C19, and a moderate inhibitor of CYP3A4. In
addition to the observed/documented interactions mentioned below,
there is a risk of increased plasma concentration of other
compounds metabolized by CYP2C9, CYP2C19, and CYP3A4 coadministered
with fluconazole. Therefore, caution should be exercised when using
these combinations and the patients should be carefully monitored.
The enzyme inhibiting effect of fluconazole persists 4 to 5 days
after discontinuation of fluconazole treatment due to the long
half-life of fluconazole. Clinically or potentially significant
drug interactions between fluconazole and the following
agents/classes have been observed. These are described in greater
detail below:</p>
<p>Oral Hypoglycemics<br>
Coumarin-type Anticoagulants<br>
Phenytoin<br>
Cyclosporine<br>
Rifampin<br>
Theophylline<br>
Terfenadine<br>
Cisapride<br>
Astemizole<br>
Rifabutin<br>
Voriconazole<br>
Tacrolimus<br>
Short-acting Benzodiazepines<br>
Tofacitinib<br>
Triazolam<br>
Oral Contraceptives<br>
Pimozide<br>
Quinidine<br>
Hydrochlorothiazide<br>
Alfentanil<br>
Amitriptyline, Nortriptyline<br>
Amphotericin B<br>
Azithromycin<br>
Carbamazepine<br>
Calcium Channel Blockers<br>
Celecoxib<br>
Cyclophosphamide<br>
Fentanyl<br>
Halofantrine<br>
HMG-CoA Reductase Inhibitors<br>
Losartan<br>
Methadone<br>
Non-Steroidal Anti-Inflammatory Drugs<br>
Prednisone<br>
Saquinavir<br>
Sirolimus<br>
Vinca Alkaloids<br>
Vitamin A<br>
Zidovudine</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_acdacc5d-c8e9-4330-a232-7187a33a1649" id=
"i4i_section_id_acdacc5d-c8e9-4330-a232-7187a33a1649"></a> <a name=
"section-7.2.1" id="section-7.2.1"></a>
<h3><span class="Bold"><span class="Italics">Oral
Hypoglycemics</span></span></h3>
<p class="First">Clinically significant hypoglycemia may be
precipitated by the use of fluconazole with oral hypoglycemic
agents; one fatality has been reported from hypoglycemia in
association with combined fluconazole and glyburide use.
Fluconazole reduces the metabolism of tolbutamide, glyburide, and
glipizide and increases the plasma concentration of these agents.
When fluconazole is used concomitantly with these or other
sulfonylurea oral hypoglycemic agents, blood glucose concentrations
should be carefully monitored and the dose of the sulfonylurea
should be adjusted as necessary. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_a2c86a5d-009a-4e0e-8030-94f5ad5ec7ff" id=
"i4i_section_id_a2c86a5d-009a-4e0e-8030-94f5ad5ec7ff"></a> <a name=
"section-7.2.2" id="section-7.2.2"></a>
<h3><span class="Bold"><span class="Italics">Coumarin-type
Anticoagulants</span></span></h3>
<p class="First">Prothrombin time may be increased in patients
receiving concomitant fluconazole and coumarin-type anticoagulants.
In post-marketing experience, as with other azole antifungals,
bleeding events (bruising, epistaxis, gastrointestinal bleeding,
hematuria, and melena) have been reported in association with
increases in prothrombin time in patients receiving fluconazole
concurrently with warfarin. Careful monitoring of prothrombin time
in patients receiving fluconazole and coumarin-type anticoagulants
is recommended. Dose adjustment of warfarin may be necessary. (See
<a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3ffb69f5-d55a-495f-86c2-adf7adad250b" id=
"i4i_section_id_3ffb69f5-d55a-495f-86c2-adf7adad250b"></a> <a name=
"section-7.2.3" id="section-7.2.3"></a>
<h3><span class="Bold"><span class=
"Italics">Phenytoin</span></span></h3>
<p class="First">Fluconazole increases the plasma concentrations of
phenytoin. Careful monitoring of phenytoin concentrations in
patients receiving fluconazole and phenytoin is recommended. (See
<a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2c8af3f6-028c-4566-b6e3-30610fed0f6f" id=
"i4i_section_id_2c8af3f6-028c-4566-b6e3-30610fed0f6f"></a> <a name=
"section-7.2.4" id="section-7.2.4"></a>
<h3><span class="Bold"><span class=
"Italics">Cyclosporine</span></span></h3>
<p class="First">Fluconazole significantly increases cyclosporine
levels in renal transplant patients with or without renal
impairment. Careful monitoring of cyclosporine concentrations and
serum creatinine is recommended in patients receiving fluconazole
and cyclosporine. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.) This combination may
be used by reducing the dosage of cyclosporine depending on
cyclosporine concentration.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b7b913f1-c2ca-46e2-87c2-8f41c8a0013b" id=
"i4i_section_id_b7b913f1-c2ca-46e2-87c2-8f41c8a0013b"></a> <a name=
"section-7.2.5" id="section-7.2.5"></a>
<h3><span class="Bold"><span class=
"Italics">Rifampin</span></span></h3>
<p class="First">Rifampin enhances the metabolism of concurrently
administered fluconazole. Depending on clinical circumstances,
consideration should be given to increasing the dose of fluconazole
when it is administered with rifampin. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_bf3470f1-ceca-46b1-97f2-18ef4f47854f" id=
"i4i_section_id_bf3470f1-ceca-46b1-97f2-18ef4f47854f"></a> <a name=
"section-7.2.6" id="section-7.2.6"></a>
<h3><span class="Bold"><span class=
"Italics">Theophylline</span></span></h3>
<p class="First">Fluconazole increases the serum concentrations of
theophylline. Careful monitoring of serum theophylline
concentrations in patients receiving fluconazole and theophylline
is recommended. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d2a6a9be-ff57-4ebc-9961-e642802f60d7" id=
"i4i_section_id_d2a6a9be-ff57-4ebc-9961-e642802f60d7"></a> <a name=
"section-7.2.7" id="section-7.2.7"></a>
<h3><span class="Bold"><span class=
"Italics">Terfenadine</span></span></h3>
<p class="First">Because of the occurrence of serious cardiac
dysrhythmias secondary to prolongation of the QTc interval in
patients receiving azole antifungals in conjunction with
terfenadine, interaction studies have been performed. One study at
a 200 mg daily dose of fluconazole failed to demonstrate a
prolongation in QTc interval. Another study at a 400 mg and 800 mg
daily dose of fluconazole demonstrated that fluconazole taken in
doses of 400 mg per day or greater significantly increases plasma
levels of terfenadine when taken concomitantly. The combined use of
fluconazole at doses of 400 mg or greater with terfenadine is
contraindicated. (See <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>
and <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.) The coadministration
of fluconazole at doses lower than 400 mg/day with terfenadine
should be carefully monitored.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_190af476-10b5-4c55-b8bb-84069b9535c6" id=
"i4i_section_id_190af476-10b5-4c55-b8bb-84069b9535c6"></a> <a name=
"section-7.2.8" id="section-7.2.8"></a>
<h3><span class="Bold"><span class=
"Italics">Cisapride</span></span></h3>
<p class="First">There have been reports of cardiac events,
including torsade de pointes, in patients to whom fluconazole and
cisapride were coadministered. A controlled study found that
concomitant fluconazole 200 mg once daily and cisapride 20 mg four
times a day yielded a significant increase in cisapride plasma
levels and prolongation of QTc interval. The combined use of
fluconazole with cisapride is contraindicated. (See <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>
and <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_11905454-10f4-4079-a088-d01f2dd1e9ce" id=
"i4i_section_id_11905454-10f4-4079-a088-d01f2dd1e9ce"></a> <a name=
"section-7.2.9" id="section-7.2.9"></a>
<h3><span class="Bold"><span class=
"Italics">Astemizole</span></span></h3>
<p class="First">Concomitant administration of fluconazole with
astemizole may decrease the clearance of astemizole. Resulting
increased plasma concentrations of astemizole can lead to QT
prolongation and rare occurrences of torsade de pointes.
Coadministration of fluconazole and astemizole is
contraindicated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_4e0b5cf7-97c7-4ea4-bbdd-fb1e18011a77" id=
"i4i_section_id_4e0b5cf7-97c7-4ea4-bbdd-fb1e18011a77"></a> <a name=
"section-7.2.10" id="section-7.2.10"></a>
<h3><span class="Bold"><span class=
"Italics">Rifabutin</span></span></h3>
<p class="First">There have been reports that an interaction exists
when fluconazole is administered concomitantly with rifabutin,
leading to increased serum levels of rifabutin up to 80%. There
have been reports of uveitis in patients to whom fluconazole and
rifabutin were coadministered. Patients receiving rifabutin and
fluconazole concomitantly should be carefully monitored. (See
<a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ec30acc6-26a9-4462-9014-d11e77f972bc" id=
"i4i_section_id_ec30acc6-26a9-4462-9014-d11e77f972bc"></a> <a name=
"section-7.2.11" id="section-7.2.11"></a>
<h3><span class="Bold"><span class=
"Italics">Voriconazole</span></span></h3>
<p class="First">Avoid concomitant administration of voriconazole
and fluconazole. Monitoring for adverse events and toxicity related
to voriconazole is recommended; especially, if voriconazole is
started within 24 hours after the last dose of fluconazole. (See
<a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_564f2942-75b1-47ba-b103-c3339b467a28" id=
"i4i_section_id_564f2942-75b1-47ba-b103-c3339b467a28"></a> <a name=
"section-7.2.12" id="section-7.2.12"></a>
<h3><span class="Bold"><span class=
"Italics">Tacrolimus</span></span></h3>
<p class="First">Fluconazole may increase the serum concentrations
of orally administered tacrolimus up to 5 times due to inhibition
of tacrolimus metabolism through CYP3A4 in the intestines. No
significant pharmacokinetic changes have been observed when
tacrolimus is given intravenously. Increased tacrolimus levels have
been associated with nephrotoxicity. Dosage of orally administered
tacrolimus should be decreased depending on tacrolimus
concentration. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5f03ad72-0d22-4524-81c1-bc45a2d1ddc4" id=
"i4i_section_id_5f03ad72-0d22-4524-81c1-bc45a2d1ddc4"></a> <a name=
"section-7.2.13" id="section-7.2.13"></a>
<h3><span class="Bold"><span class="Italics">Short-acting
Benzodiazepines</span></span></h3>
<p class="First">Following oral administration of midazolam,
fluconazole resulted in substantial increases in midazolam
concentrations and psychomotor effects. This effect on midazolam
appears to be more pronounced following oral administration of
fluconazole than with fluconazole administered intravenously. If
short-acting benzodiazepines, which are metabolized by the
cytochrome P450 system, are concomitantly administered with
fluconazole, consideration should be given to decreasing the
benzodiazepine dosage, and the patients should be appropriately
monitored. (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_64be4994-59c6-4c7b-bd69-6026fde8c534" id=
"ID_64be4994-59c6-4c7b-bd69-6026fde8c534"></a> <a name=
"section-7.2.14" id="section-7.2.14"></a>
<h3><span class="Bold"><span class=
"Italics">Tofacitinib</span></span></h3>
<p class="First">Systemic exposure to tofacitinib is increased when
tofacitinib is coadministered with fluconazole, a combined moderate
CYP3A4 and potent CYP2C19 inhibitor. Reduce the dose of tofacitinib
when given concomitantly with fluconazole (i.e., from 5 mg twice
daily to 5 mg once daily as instructed in the XELJANZ<span class=
"Sup">®</span> [tofacitinib] label). (See <a href=
"#i4i_section_id_2a7887e3-259c-495d-9b74-f97b6a1727d1">CLINICAL
PHARMACOLOGY: Drug Interaction Studies</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_47e1f829-45a4-405f-9f26-9f80dd04e093" id=
"ID_47e1f829-45a4-405f-9f26-9f80dd04e093"></a> <a name=
"section-7.2.15" id="section-7.2.15"></a>
<h3><span class="Bold"><span class=
"Italics">Triazolam</span></span></h3>
<p class="First">Fluconazole increases the AUC of triazolam (single
dose) by approximately 50%, C<span class="Sub">max</span> by 20% to
32%, and increases t<span class="Sub">½</span> by 25% to 50% due to
the inhibition of metabolism of triazolam. Dosage adjustments of
triazolam may be necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c3488881-8ab8-4708-9699-cc1ae2860e44" id=
"i4i_section_id_c3488881-8ab8-4708-9699-cc1ae2860e44"></a> <a name=
"section-7.2.16" id="section-7.2.16"></a>
<h3><span class="Bold"><span class="Italics">Oral
Contraceptives</span></span></h3>
<p class="First">Two pharmacokinetic studies with a combined oral
contraceptive have been performed using multiple doses of
fluconazole. There were no relevant effects on hormone level in the
50 mg fluconazole study, while at 200 mg daily, the AUCs of ethinyl
estradiol and levonorgestrel were increased 40% and 24%,
respectively. Thus, multiple dose use of fluconazole at these doses
is unlikely to have an effect on the efficacy of the combined oral
contraceptive.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_f111c3c6-9a19-43e3-91f6-90f4dd7b5504" id=
"i4i_section_id_f111c3c6-9a19-43e3-91f6-90f4dd7b5504"></a> <a name=
"section-7.2.17" id="section-7.2.17"></a>
<h3><span class="Bold"><span class=
"Italics">Pimozide</span></span></h3>
<p class="First">Although not studied <span class="Italics">in
vitro</span> or <span class="Italics">in vivo</span>, concomitant
administration of fluconazole with pimozide may result in
inhibition of pimozide metabolism. Increased pimozide plasma
concentrations can lead to QT prolongation and rare occurrences of
torsade de pointes. Coadministration of fluconazole and pimozide is
contraindicated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_ae7a8d16-b321-4325-b899-5da02f39c0db" id=
"ID_ae7a8d16-b321-4325-b899-5da02f39c0db"></a> <a name=
"section-7.2.18" id="section-7.2.18"></a>
<h3><span class="Bold"><span class=
"Italics">Quinidine</span></span></h3>
<p class="First">Although not studied <span class="Italics">in
vitro</span> or <span class="Italics">in vivo</span>, concomitant
administration of fluconazole with quinidine may result in
inhibition of quinidine metabolism. Use of quinidine has been
associated with QT prolongation and rare occurrences of torsade de
pointes. Coadministration of fluconazole and quinidine is
contraindicated. (See <a href=
"#i4i_contraindications_id_31b27548-bdd2-445d-b195-59b9890cbf7d">CONTRAINDICATIONS</a>.<span class="Bold">)</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_edcc6702-17de-40ac-a803-757cad3f0a50" id=
"i4i_section_id_edcc6702-17de-40ac-a803-757cad3f0a50"></a> <a name=
"section-7.2.19" id="section-7.2.19"></a>
<h3><span class="Bold"><span class=
"Italics">Hydrochlorothiazide</span></span></h3>
<p class="First">In a pharmacokinetic interaction study,
coadministration of multiple dose hydrochlorothiazide to healthy
volunteers receiving fluconazole increased plasma concentrations of
fluconazole by 40%. An effect of this magnitude should not
necessitate a change in the fluconazole dose regimen in subjects
receiving concomitant diuretics.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3922152e-c6fe-4039-b55c-7646aa518715" id=
"i4i_section_id_3922152e-c6fe-4039-b55c-7646aa518715"></a> <a name=
"section-7.2.20" id="section-7.2.20"></a>
<h3><span class="Bold"><span class=
"Italics">Alfentanil</span></span></h3>
<p class="First">A study observed a reduction in clearance and
distribution volume as well as prolongation of t<span class=
"Sub">½</span> of alfentanil following concomitant treatment with
fluconazole. A possible mechanism of action is fluconazole’s
inhibition of CYP3A4. Dosage adjustment of alfentanil may be
necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6a902469-4983-4e4c-a5f9-0aaf5d3050c2" id=
"i4i_section_id_6a902469-4983-4e4c-a5f9-0aaf5d3050c2"></a> <a name=
"section-7.2.21" id="section-7.2.21"></a>
<h3><span class="Bold"><span class="Italics">Amitriptyline,
Nortriptyline</span></span></h3>
<p class="First">Fluconazole increases the effect of amitriptyline
and nortriptyline. 5-nortriptyline and/or S-amitriptyline may be
measured at initiation of the combination therapy and after one
week. Dosage of amitriptyline/nortriptyline should be adjusted, if
necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5dc928cb-f9e0-4605-a137-779ad1fe1422" id=
"i4i_section_id_5dc928cb-f9e0-4605-a137-779ad1fe1422"></a> <a name=
"section-7.2.22" id="section-7.2.22"></a>
<h3><span class="Bold"><span class="Italics">Amphotericin
B</span></span></h3>
<p class="First">Concurrent administration of fluconazole and
amphotericin B in infected normal and immunosuppressed mice showed
the following results: a small additive antifungal effect in
systemic infection with <span class="Italics">C. albicans</span>,
no interaction in intracranial infection with <span class=
"Italics">Cryptococcus neoformans</span>, and antagonism of the two
drugs in systemic infection with <span class="Italics">A.
fumigatus</span>. The clinical significance of results obtained in
these studies is unknown.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5d8033ed-3951-4149-a0fd-89994495bb79" id=
"i4i_section_id_5d8033ed-3951-4149-a0fd-89994495bb79"></a> <a name=
"section-7.2.23" id="section-7.2.23"></a>
<h3><span class="Bold"><span class=
"Italics">Azithromycin</span></span></h3>
<p class="First">An open-label, randomized, three-way crossover
study in 18 healthy subjects assessed the effect of a single 1200
mg oral dose of azithromycin on the pharmacokinetics of a single
800 mg oral dose of fluconazole as well as the effects of
fluconazole on the pharmacokinetics of azithromycin. There was no
significant pharmacokinetic interaction between fluconazole and
azithromycin.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3077e829-8fbf-499f-b7f3-308980919ecc" id=
"i4i_section_id_3077e829-8fbf-499f-b7f3-308980919ecc"></a> <a name=
"section-7.2.24" id="section-7.2.24"></a>
<h3><span class="Bold"><span class=
"Italics">Carbamazepine</span></span></h3>
<p class="First">Fluconazole inhibits the metabolism of
carbamazepine and an increase in serum carbamazepine of 30% has
been observed. There is a risk of developing carbamazepine
toxicity. Dosage adjustment of carbamazepine may be necessary
depending on concentration measurements/effect.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_8c79dd28-b810-4e90-8ac4-f94606c81d91" id=
"i4i_section_id_8c79dd28-b810-4e90-8ac4-f94606c81d91"></a> <a name=
"section-7.2.25" id="section-7.2.25"></a>
<h3><span class="Bold"><span class="Italics">Calcium Channel
Blockers</span></span></h3>
<p class="First">Certain calcium channel antagonists (nifedipine,
isradipine, amlodipine, verapamil, and felodipine) are metabolized
by CYP3A4. Fluconazole has the potential to increase the systemic
exposure of the calcium channel antagonists. Frequent monitoring
for adverse events is recommended.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_3a91d389-5c2c-43c2-b11a-65a4c8006a49" id=
"i4i_section_id_3a91d389-5c2c-43c2-b11a-65a4c8006a49"></a> <a name=
"section-7.2.26" id="section-7.2.26"></a>
<h3><span class="Bold"><span class=
"Italics">Celecoxib</span></span></h3>
<p class="First">During concomitant treatment with fluconazole (200
mg daily) and celecoxib (200 mg), the celecoxib C<span class=
"Sub">max</span> and AUC increased by 68% and 134%, respectively.
Half of the celecoxib dose may be necessary when combined with
fluconazole.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_8e40cb00-e508-4503-a853-96ba6b8a191c" id=
"i4i_section_id_8e40cb00-e508-4503-a853-96ba6b8a191c"></a> <a name=
"section-7.2.27" id="section-7.2.27"></a>
<h3><span class="Bold"><span class=
"Italics">Cyclophosphamide</span></span></h3>
<p class="First">Combination therapy with cyclophosphamide and
fluconazole results in an increase in serum bilirubin and serum
creatinine. The combination may be used while taking increased
consideration to the risk of increased serum bilirubin and serum
creatinine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_e0f49320-30bc-49ff-b801-84bd333e1600" id=
"i4i_section_id_e0f49320-30bc-49ff-b801-84bd333e1600"></a> <a name=
"section-7.2.28" id="section-7.2.28"></a>
<h3><span class="Bold"><span class=
"Italics">Fentanyl</span></span></h3>
<p class="First">One fatal case of possible fentanyl fluconazole
interaction was reported. The author judged that the patient died
from fentanyl intoxication. Furthermore, in a randomized crossover
study with 12 healthy volunteers it was shown that fluconazole
delayed the elimination of fentanyl significantly. Elevated
fentanyl concentration may lead to respiratory depression.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_33053177-a1c9-44f2-a89c-acdd21e2d44d" id=
"i4i_section_id_33053177-a1c9-44f2-a89c-acdd21e2d44d"></a> <a name=
"section-7.2.29" id="section-7.2.29"></a>
<h3><span class="Bold"><span class=
"Italics">Halofantrine</span></span></h3>
<p class="First">Fluconazole can increase halofantrine plasma
concentration due to an inhibitory effect on CYP3A4.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_093b8939-a3d1-437b-b7c8-219f817f342f" id=
"i4i_section_id_093b8939-a3d1-437b-b7c8-219f817f342f"></a> <a name=
"section-7.2.30" id="section-7.2.30"></a>
<h3><span class="Bold"><span class="Italics">HMG-CoA Reductase
Inhibitors</span></span></h3>
<p class="First">The risk of myopathy and rhabdomyolysis increases
when fluconazole is coadministered with HMG-CoA reductase
inhibitors metabolized through CYP3A4, such as atorvastatin and
simvastatin, or through CYP2C9, such as fluvastatin. If concomitant
therapy is necessary, the patient should be observed for symptoms
of myopathy and rhabdomyolysis and creatinine kinase should be
monitored. HMG-CoA reductase inhibitors should be discontinued if a
marked increase in creatinine kinase is observed or
myopathy/rhabdomyolysis is diagnosed or suspected.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_cfcf488a-437b-4912-ad36-0e54ea240537" id=
"i4i_section_id_cfcf488a-437b-4912-ad36-0e54ea240537"></a> <a name=
"section-7.2.31" id="section-7.2.31"></a>
<h3><span class="Bold"><span class=
"Italics">Losartan</span></span></h3>
<p class="First">Fluconazole inhibits the metabolism of losartan to
its active metabolite (E-31 74) which is responsible for most of
the angiotensin Il-receptor antagonism which occurs during
treatment with losartan. Patients should have their blood pressure
monitored continuously.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_fcaba45a-22cd-44a1-abfd-9a6c7e41d0ad" id=
"i4i_section_id_fcaba45a-22cd-44a1-abfd-9a6c7e41d0ad"></a> <a name=
"section-7.2.32" id="section-7.2.32"></a>
<h3><span class="Bold"><span class=
"Italics">Methadone</span></span></h3>
<p class="First">Fluconazole may enhance the serum concentration of
methadone. Dosage adjustment of methadone may be necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_0d4b1902-5423-416c-81fe-6e6b96c08ef9" id=
"ID_0d4b1902-5423-416c-81fe-6e6b96c08ef9"></a> <a name=
"section-7.2.33" id="section-7.2.33"></a>
<h3><span class="Bold"><span class="Italics">Non-Steroidal
Anti-Inflammatory Drugs</span></span></h3>
<p class="First">The C<span class="Sub">max</span> and AUC of
flurbiprofen were increased by 23% and 81%, respectively, when
coadministered with fluconazole compared to administration of
flurbiprofen alone. Similarly, the C<span class="Sub">max</span>
and AUC of the pharmacologically active isomer [S(+)-ibuprofen]
were increased by 15% and 82%, respectively, when fluconazole was
coadministered with racemic ibuprofen (400 mg) compared to
administration of racemic ibuprofen alone.</p>
<p>Although not specifically studied, fluconazole has the potential
to increase the systemic exposure of other NSAIDs that are
metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam,
diclofenac). Frequent monitoring for adverse events and toxicity
related to NSAIDs is recommended. Adjustment of dosage of NSAIDs
may be needed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_6ad67dcd-3f6a-4f4a-80db-44e79c58ec58" id=
"i4i_section_id_6ad67dcd-3f6a-4f4a-80db-44e79c58ec58"></a> <a name=
"section-7.2.34" id="section-7.2.34"></a>
<h3><span class="Bold"><span class=
"Italics">Prednisone</span></span></h3>
<p class="First">There was a case report that a liver-transplanted
patient treated with prednisone developed acute adrenal cortex
insufficiency when a 3 month therapy with fluconazole was
discontinued. The discontinuation of fluconazole presumably caused
an enhanced CYP3A4 activity which led to increased metabolism of
prednisone. Patients on long-term treatment with fluconazole and
prednisone should be carefully monitored for adrenal cortex
insufficiency when fluconazole is discontinued.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_0d2f3384-0640-47e0-86c0-77904d58e6e8" id=
"i4i_section_id_0d2f3384-0640-47e0-86c0-77904d58e6e8"></a> <a name=
"section-7.2.35" id="section-7.2.35"></a>
<h3><span class="Bold"><span class=
"Italics">Saquinavir</span></span></h3>
<p class="First">Fluconazole increases the AUC of saquinavir by
approximately 50%, C<span class="Sub">max</span> by approximately
55%, and decreases clearance of saquinavir by approximately 50% due
to inhibition of saquinavir’s hepatic metabolism by CYP3A4 and
inhibition of P-glycoprotein. Dosage adjustment of saquinavir may
be necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ca7460fe-a526-4032-adf5-6189b0fa2e19" id=
"i4i_section_id_ca7460fe-a526-4032-adf5-6189b0fa2e19"></a> <a name=
"section-7.2.36" id="section-7.2.36"></a>
<h3><span class="Bold"><span class=
"Italics">Sirolimus</span></span></h3>
<p class="First">Fluconazole increases plasma concentrations of
sirolimus presumably by inhibiting the metabolism of sirolimus via
CYP3A4 and P-glycoprotein. This combination may be used with a
dosage adjustment of sirolimus depending on the
effect/concentration measurements.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_40d07982-dca6-4bcb-980a-39623c01193a" id=
"i4i_section_id_40d07982-dca6-4bcb-980a-39623c01193a"></a> <a name=
"section-7.2.37" id="section-7.2.37"></a>
<h3><span class="Bold"><span class="Italics">Vinca
Alkaloids</span></span></h3>
<p class="First">Although not studied, fluconazole may increase the
plasma levels of the vinca alkaloids (e.g., vincristine and
vinblastine) and lead to neurotoxicity, which is possibly due to an
inhibitory effect on CYP3A4.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ea9af2db-a6e9-4cd6-8820-e37a762dfcae" id=
"i4i_section_id_ea9af2db-a6e9-4cd6-8820-e37a762dfcae"></a> <a name=
"section-7.2.38" id="section-7.2.38"></a>
<h3><span class="Bold"><span class="Italics">Vitamin
A</span></span></h3>
<p class="First">Based on a case report in one patient receiving
combination therapy with all-trans retinoid acid (an acid form of
vitamin A) and fluconazole, CNS related undesirable effects have
developed in the form of pseudotumour cerebri, which disappeared
after discontinuation of fluconazole treatment. This combination
may be used but the incidence of CNS related undesirable effects
should be borne in mind.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_0dc50f86-7b21-4290-b9cd-c9a93f515c24" id=
"i4i_section_id_0dc50f86-7b21-4290-b9cd-c9a93f515c24"></a> <a name=
"section-7.2.39" id="section-7.2.39"></a>
<h3><span class="Bold"><span class=
"Italics">Zidovudine</span></span></h3>
<p class="First">Fluconazole increases C<span class=
"Sub">max</span> and AUC of zidovudine by 84% and 74%,
respectively, due to an approximately 45% decrease in oral
zidovudine clearance. The half-life of zidovudine was likewise
prolonged by approximately 128% following combination therapy with
fluconazole. Patients receiving this combination should be
monitored for the development of zidovudine-related adverse
reactions. Dosage reduction of zidovudine may be considered.</p>
<p>Physicians should be aware that interaction studies with
medications other than those listed in the <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a> section have not been conducted, but such
interactions may occur.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_7e4bffcb-8530-4f6c-b5fe-0ec7c75ffa35" id=
"i4i_section_id_7e4bffcb-8530-4f6c-b5fe-0ec7c75ffa35"></a> <a name=
"section-7.3" id="section-7.3"></a>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Fluconazole showed no evidence of carcinogenic
potential in mice and rats treated orally for 24 months at doses of
2.5, 5, or 10 mg/kg/day (approximately 2 to 7 times the recommended
human dose). Male rats treated with 5 and 10 mg/kg/day had an
increased incidence of hepatocellular adenomas.</p>
<p>Fluconazole, with or without metabolic activation, was negative
in tests for mutagenicity in four strains of <span class=
"Italics">S. typhimurium</span>, and in the mouse lymphoma L5178Y
system. Cytogenetic studies <span class="Italics">in vivo</span>
(murine bone marrow cells, following oral administration of
fluconazole) and <span class="Italics">in vitro</span> (human
lymphocytes exposed to fluconazole at 1000 mcg/mL) showed no
evidence of chromosomal mutations.</p>
<p>Fluconazole did not affect the fertility of male or female rats
treated orally with daily doses of 5, 10, or 20 mg/kg or with
parenteral doses of 5, 25, or 75 mg/kg, although the onset of
parturition was slightly delayed at 20 mg/kg PO. In an intravenous
perinatal study in rats at 5, 20, and 40 mg/kg, dystocia and
prolongation of parturition were observed in a few dams at 20 mg/kg
(approximately 5 to 15 times the recommended human dose) and 40
mg/kg, but not at 5 mg/kg. The disturbances in parturition were
reflected by a slight increase in the number of still-born pups and
decrease of neonatal survival at these dose levels. The effects on
parturition in rats are consistent with the species specific
estrogen-lowering property produced by high doses of fluconazole.
Such a hormone change has not been observed in women treated with
fluconazole. (See <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_56083f1a-dee2-427f-843e-bf3d80cd7eef" id=
"i4i_section_id_56083f1a-dee2-427f-843e-bf3d80cd7eef"></a> <a name=
"section-7.4" id="section-7.4"></a>
<h2>Pregnancy</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_718a6d20-4a89-40aa-9d1a-605c6559fd44" id=
"ID_718a6d20-4a89-40aa-9d1a-605c6559fd44"></a> <a name=
"section-7.4.1" id="section-7.4.1"></a>
<h3><span class="Bold"><span class="Italics">Teratogenic
Effects</span></span></h3>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_d24d718c-a40e-4d23-a67c-8111e41dc343" id=
"ID_d24d718c-a40e-4d23-a67c-8111e41dc343"></a> <a name=
"section-7.4.1.1" id="section-7.4.1.1"></a>
<h4>Pregnancy Category C</h4>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_3b383576-0723-4074-88a5-e09b5b1ca45c" id=
"ID_3b383576-0723-4074-88a5-e09b5b1ca45c"></a> <a name=
"section-7.4.1.1.1" id="section-7.4.1.1.1"></a>
<h5>Single 150 mg Tablet Use For Vaginal Candidiasis</h5>
<p class="First">There are no adequate and well-controlled studies
of fluconazole in pregnant women. Available human data do not
suggest an increased risk of congenital anomalies following a
single maternal dose of 150 mg.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_9edf9928-04e7-4d94-bd5a-710ded77976f" id=
"ID_9edf9928-04e7-4d94-bd5a-710ded77976f"></a> <a name=
"section-7.4.1.2" id="section-7.4.1.2"></a>
<h4>Pregnancy Category D</h4>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_1ae0e7df-7ec7-49a1-b4c7-ce21d57f491d" id=
"ID_1ae0e7df-7ec7-49a1-b4c7-ce21d57f491d"></a> <a name=
"section-7.4.1.2.1" id="section-7.4.1.2.1"></a>
<h5>All Other Indications</h5>
<p class="First">A few published case reports describe a rare
pattern of distinct congenital anomalies in infants exposed
<span class="Italics">in utero</span> to high dose maternal
fluconazole (400 to 800 mg/day) during most or all of the first
trimester. These reported anomalies are similar to those seen in
animal studies. If this drug is used during pregnancy, or if the
patient becomes pregnant while taking the drug, the patient should
be informed of the potential hazard to the fetus. (See <a href=
"#i4i_warnings_id_72427026-310b-4b8e-8c83-c7159e5236c6">WARNINGS:
Use in Pregnancy</a>.)</p>
<p>Human Data: Several published epidemiologic studies do not
suggest an increased risk of congenital anomalies associated with
low dose exposure to fluconazole in pregnancy (most subjects
received a single oral dose of 150 mg). A few published case
reports describe a distinctive and rare pattern of birth defects
among infants whose mothers received high-dose (400 to 800 mg/day)
fluconazole during most or all of the first trimester of pregnancy.
The features seen in these infants include: brachycephaly, abnormal
facies, abnormal calvarial development, cleft palate, femoral
bowing, thin ribs and long bones, arthrogryposis, and congenital
heart disease. These effects are similar to those seen in animal
studies.</p>
<p>Animal Data: Fluconazole was administered orally to pregnant
rabbits during organogenesis in two studies at doses of 5, 10, and
20 mg/kg and at 5, 25, and 75 mg/kg, respectively. Maternal weight
gain was impaired at all dose levels (approximately 0.25 to 4 times
the 400 mg clinical dose based on BSA), and abortions occurred at
75 mg/kg (approximately 4 times the 400 mg clinical dose based on
BSA); no adverse fetal effects were observed.</p>
<p>In several studies in which pregnant rats received fluconazole
orally during organogenesis, maternal weight gain was impaired and
placental weights were increased at 25 mg/kg. There were no fetal
effects at 5 or 10 mg/kg; increases in fetal anatomical variants
(supernumerary ribs, renal pelvis dilation) and delays in
ossification were observed at 25 and 50 mg/kg and higher doses. At
doses ranging from 80 to 320 mg/kg (approximately 2 to 8 times the
400 mg clinical dose based on BSA), embryolethality in rats was
increased and fetal abnormalities included wavy ribs, cleft palate,
and abnormal cranio-facial ossification. These effects are
consistent with the inhibition of estrogen synthesis in rats and
may be a result of known effects of lowered estrogen on pregnancy,
organogenesis, and parturition.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_ea11180b-b390-420e-82de-48cfdddea2b4" id=
"i4i_section_id_ea11180b-b390-420e-82de-48cfdddea2b4"></a> <a name=
"section-7.5" id="section-7.5"></a>
<h2>Nursing Mothers</h2>
<p class="First">Fluconazole is secreted in human milk at
concentrations similar to maternal plasma concentrations. Caution
should be exercised when fluconazole is administered to a nursing
woman.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_4853f3a7-a353-48b1-81c2-1edc260089e5" id=
"i4i_section_id_4853f3a7-a353-48b1-81c2-1edc260089e5"></a> <a name=
"section-7.6" id="section-7.6"></a>
<h2>Pediatric Use</h2>
<p class="First">An open-label, randomized, controlled trial has
shown fluconazole to be effective in the treatment of oropharyngeal
candidiasis in children 6 months to 13 years of age. (See <a href=
"#i4i_clinical_studies_id_ebe54b2c-2c38-4eeb-91de-ca3a681172e2">CLINICAL
STUDIES</a>.)</p>
<p>The use of fluconazole in children with cryptococcal meningitis,
<span class="Italics">Candida</span> esophagitis, or systemic
<span class="Italics">Candida</span> infections is supported by the
efficacy shown for these indications in adults and by the results
from several small noncomparative pediatric clinical studies. In
addition, pharmacokinetic studies in children (see <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a>) have established a dose proportionality
between children and adults. (See <a href=
"#i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14">DOSAGE
AND ADMINISTRATION</a>.)</p>
<p>In a noncomparative study of children with serious systemic
fungal infections, most of which were candidemia, the effectiveness
of fluconazole was similar to that reported for the treatment of
candidemia in adults. Of 17 subjects with culture-confirmed
candidemia, 11 of 14 (79%) with baseline symptoms (three were
asymptomatic) had a clinical cure; 13/15 (87%) of evaluable
patients had a mycologic cure at the end of treatment but two of
these patients relapsed at 10 and 18 days, respectively, following
cessation of therapy.</p>
<p>The efficacy of fluconazole for the suppression of cryptococcal
meningitis was successful in 4 of 5 children treated in a
compassionate-use study of fluconazole for the treatment of
life-threatening or serious mycosis. There is no information
regarding the efficacy of fluconazole for primary treatment of
cryptococcal meningitis in children.</p>
<p>The safety profile of fluconazole in children has been studied
in 577 children ages 1 day to 17 years who received doses ranging
from 1 to 15 mg/kg/day for 1 to 1,616 days. (See <a href=
"#i4i_adverse_effects_id_52cbbd8c-9715-416b-ad57-d207d8e7c2e6">ADVERSE
REACTIONS</a>.)</p>
<p>Efficacy of fluconazole has not been established in infants less
than 6 months of age. (See <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a>.) A small number of patients (29) ranging
in age from 1 day to 6 months have been treated safely with
fluconazole.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5cf11698-e3a4-4e9a-b24e-640e3a0cdfa0" id=
"i4i_section_id_5cf11698-e3a4-4e9a-b24e-640e3a0cdfa0"></a> <a name=
"section-7.7" id="section-7.7"></a>
<h2>Geriatric Use</h2>
<p class="First">In non-AIDS patients, side effects possibly
related to fluconazole treatment were reported in fewer patients
aged 65 and older (9%, n = 339) than for younger patients (14%,<br>
n = 2,240). However, there was no consistent difference between the
older and younger patients with respect to individual side effects.
Of the most frequently reported (&gt; 1%) side effects, rash,
vomiting, and diarrhea occurred in greater proportions of older
patients. Similar proportions of older patients (2.4%) and younger
patients (1.5%) discontinued fluconazole therapy because of side
effects. In post-marketing experience, spontaneous reports of
anemia and acute renal failure were more frequent among patients 65
years of age or older than in those between 12 and 65 years of age.
Because of the voluntary nature of the reports and the natural
increase in the incidence of anemia and renal failure in the
elderly, it is however not possible to establish a casual
relationship to drug exposure.</p>
<p>Controlled clinical trials of fluconazole did not include
sufficient numbers of patients aged 65 and older to evaluate
whether they respond differently from younger patients in each
indication. Other reported clinical experience has not identified
differences in responses between the elderly and younger
patients.</p>
<p>Fluconazole is primarily cleared by renal excretion as unchanged
drug. Because elderly patients are more likely to have decreased
renal function, care should be taken to adjust dose based on
creatinine clearance. It may be useful to monitor renal function.
(See <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a> and <a href=
"#i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14">DOSAGE
AND ADMINISTRATION</a>.)</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name=
"i4i_adverse_effects_id_52cbbd8c-9715-416b-ad57-d207d8e7c2e6" id=
"i4i_adverse_effects_id_52cbbd8c-9715-416b-ad57-d207d8e7c2e6"></a>
<a name="section-8" id="section-8"></a>
<p class="First">Fluconazole is generally well tolerated.</p>
<p>In some patients, particularly those with serious underlying
diseases such as AIDS and cancer, changes in renal and
hematological function test results and hepatic abnormalities have
been observed during treatment with fluconazole and comparative
agents, but the clinical significance and relationship to treatment
is uncertain.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_53043340-0e1e-49e4-a68e-7ff4e27ce6bd" id=
"i4i_section_id_53043340-0e1e-49e4-a68e-7ff4e27ce6bd"></a> <a name=
"section-8.1" id="section-8.1"></a>
<h2>In Patients Receiving a Single Dose for Vaginal
Candidiasis</h2>
<p class="First">During comparative clinical studies conducted in
the United States, 448 patients with vaginal candidiasis were
treated with fluconazole, 150 mg single dose. The overall incidence
of side effects possibly related to fluconazole was 26%. In 422
patients receiving active comparative agents, the incidence was
16%. The most common treatment-related adverse events reported in
the patients who received 150 mg single dose fluconazole for
vaginitis were headache (13%), nausea (7%), and abdominal pain
(6%). Other side effects reported with an incidence equal to or
greater than 1% included diarrhea (3%), dyspepsia (1%), dizziness
(1%), and taste perversion (1%). Most of the reported side effects
were mild to moderate in severity. Rarely, angioedema and
anaphylactic reaction have been reported in marketing
experience.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_27b85599-4477-4594-8efd-5e332b6c41f9" id=
"i4i_section_id_27b85599-4477-4594-8efd-5e332b6c41f9"></a> <a name=
"section-8.2" id="section-8.2"></a>
<h2>In Patients Receiving Multiple Doses for Other Infections</h2>
<p class="First">Sixteen percent of over 4,000 patients treated
with fluconazole in clinical trials of 7 days or more experienced
adverse events. Treatment was discontinued in 1.5% of patients due
to adverse clinical events and in 1.3% of patients due to
laboratory test abnormalities.</p>
<p>Clinical adverse events were reported more frequently in HIV
infected patients (21%) than in non-HIV infected patients (13%);
however, the patterns in HIV infected and non-HIV infected patients
were similar. The proportions of patients discontinuing therapy due
to clinical adverse events were similar in the two groups
(1.5%).</p>
<p>The following treatment-related clinical adverse events occurred
at an incidence of 1% or greater in 4,048 patients receiving
fluconazole for 7 or more days in clinical trials: nausea 3.7%,
headache 1.9%, skin rash 1.8%, vomiting 1.7%, abdominal pain 1.7%,
and diarrhea 1.5%.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_79bf6a02-a1a9-4f09-baf2-185de18bbd06" id=
"i4i_section_id_79bf6a02-a1a9-4f09-baf2-185de18bbd06"></a> <a name=
"section-8.2.1" id="section-8.2.1"></a>
<h3><span class="Bold"><span class=
"Italics">Hepatobiliary</span></span></h3>
<p class="First">In combined clinical trials and marketing
experience, there have been rare cases of serious hepatic reactions
during treatment with fluconazole. (See <a href=
"#i4i_warnings_id_72427026-310b-4b8e-8c83-c7159e5236c6">WARNINGS</a>.)
The spectrum of these hepatic reactions has ranged from mild
transient elevations in transaminases to clinical hepatitis,
cholestasis and fulminant hepatic failure, including fatalities.
Instances of fatal hepatic reactions were noted to occur primarily
in patients with serious underlying medical conditions
(predominantly AIDS or malignancy) and often while taking multiple
concomitant medications. Transient hepatic reactions, including
hepatitis and jaundice, have occurred among patients with no other
identifiable risk factors. In each of these cases, liver function
returned to baseline on discontinuation of fluconazole.</p>
<p>In two comparative trials evaluating the efficacy of fluconazole
for the suppression of relapse of cryptococcal meningitis, a
statistically significant increase was observed in median AST
(SGOT) levels from a baseline value of 30 IU/L to 41 IU/L in one
trial and 34 IU/L to<br>
66 IU/L in the other. The overall rate of serum transaminase
elevations of more than 8 times the upper limit of normal was
approximately 1% in fluconazole-treated patients in clinical
trials. These elevations occurred in patients with severe
underlying disease, predominantly AIDS or malignancies, most of
whom were receiving multiple concomitant medications, including
many known to be hepatotoxic. The incidence of abnormally elevated
serum transaminases was greater in patients taking fluconazole
concomitantly with one or more of the following medications:
rifampin, phenytoin, isoniazid, valproic acid, or oral sulfonylurea
hypoglycemic agents.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d338a1bb-afae-4747-a7a4-a88c75eea40f" id=
"i4i_section_id_d338a1bb-afae-4747-a7a4-a88c75eea40f"></a> <a name=
"section-8.3" id="section-8.3"></a>
<h2>Post-Marketing Experience</h2>
<p class="First">In addition, the following adverse events have
occurred during post-marketing experience.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_aa7733c7-35ba-49b6-bd57-da13657a23eb" id=
"i4i_section_id_aa7733c7-35ba-49b6-bd57-da13657a23eb"></a> <a name=
"section-8.3.1" id="section-8.3.1"></a>
<h3><span class="Bold"><span class=
"Italics">Immunologic</span></span></h3>
<p class="First">In rare cases, anaphylaxis (including angioedema,
face edema and pruritus) has been reported.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_5301c65f-e7c3-4235-902c-36818a9bab08" id=
"i4i_section_id_5301c65f-e7c3-4235-902c-36818a9bab08"></a> <a name=
"section-8.3.2" id="section-8.3.2"></a>
<h3><span class="Bold"><span class="Italics">Body as a
Whole</span></span></h3>
<p class="First">Asthenia, fatigue, fever, malaise.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_548ae1cc-652a-44c3-a197-ea155b263bab" id=
"i4i_section_id_548ae1cc-652a-44c3-a197-ea155b263bab"></a> <a name=
"section-8.3.3" id="section-8.3.3"></a>
<h3><span class="Bold"><span class=
"Italics">Cardiovascular</span></span></h3>
<p class="First">QT prolongation, torsade de pointes. (See <a href=
"#i4i_precautions_id_3e428022-e51c-424a-ab39-9efa4e475990">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_95058a09-44f7-4799-a6a4-c7989f62c7db" id=
"i4i_section_id_95058a09-44f7-4799-a6a4-c7989f62c7db"></a> <a name=
"section-8.3.4" id="section-8.3.4"></a>
<h3><span class="Bold"><span class="Italics">Central Nervous
System</span></span></h3>
<p class="First">Seizures, dizziness.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_df3deecb-b60c-4b27-8808-683fe7fbdc8f" id=
"i4i_section_id_df3deecb-b60c-4b27-8808-683fe7fbdc8f"></a> <a name=
"section-8.3.5" id="section-8.3.5"></a>
<h3><span class="Bold"><span class="Italics">Hematopoietic and
Lymphatic</span></span></h3>
<p class="First">Leukopenia, including neutropenia and
agranulocytosis, thrombocytopenia.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_cd605192-e1a1-451a-8b10-dd27dacfa664" id=
"i4i_section_id_cd605192-e1a1-451a-8b10-dd27dacfa664"></a> <a name=
"section-8.3.6" id="section-8.3.6"></a>
<h3><span class="Bold"><span class=
"Italics">Metabolic</span></span></h3>
<p class="First">Hypercholesterolemia, hypertriglyceridemia,
hypokalemia.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_aef9d584-05fb-4219-9e2d-d03647c570d0" id=
"i4i_section_id_aef9d584-05fb-4219-9e2d-d03647c570d0"></a> <a name=
"section-8.3.7" id="section-8.3.7"></a>
<h3><span class="Bold"><span class=
"Italics">Gastrointestinal</span></span></h3>
<p class="First">Cholestasis, dry mouth, hepatocellular damage,
dyspepsia, vomiting.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_bfdf4ee3-2842-4be8-84bd-7f821fcd37b4" id=
"i4i_section_id_bfdf4ee3-2842-4be8-84bd-7f821fcd37b4"></a> <a name=
"section-8.3.8" id="section-8.3.8"></a>
<h3><span class="Bold"><span class="Italics">Other
Senses</span></span></h3>
<p class="First">Taste perversion.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_41140503-a85d-4174-af2f-285b52200ee4" id=
"i4i_section_id_41140503-a85d-4174-af2f-285b52200ee4"></a> <a name=
"section-8.3.9" id="section-8.3.9"></a>
<h3><span class="Bold"><span class="Italics">Musculoskeletal
System</span></span></h3>
<p class="First">Myalgia.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_a3b7d294-96be-4233-b1dc-50d6785dc0be" id=
"i4i_section_id_a3b7d294-96be-4233-b1dc-50d6785dc0be"></a> <a name=
"section-8.3.10" id="section-8.3.10"></a>
<h3><span class="Bold"><span class="Italics">Nervous
System</span></span></h3>
<p class="First">Insomnia, paresthesia, somnolence, tremor,
vertigo.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_b003647e-5712-4791-a929-6fd15ff6adc1" id=
"i4i_section_id_b003647e-5712-4791-a929-6fd15ff6adc1"></a> <a name=
"section-8.3.11" id="section-8.3.11"></a>
<h3><span class="Bold"><span class="Italics">Skin and
Appendages</span></span></h3>
<p class="First">Acute generalized exanthematous-pustulosis, drug
eruption, increased sweating, exfoliative skin disorders including
Stevens-Johnson syndrome and toxic epidermal necrolysis (see
<a href=
"#i4i_warnings_id_72427026-310b-4b8e-8c83-c7159e5236c6">WARNINGS</a>),
alopecia.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_54b19a93-4243-4e05-89d1-c6d1d5d868c1" id=
"i4i_section_id_54b19a93-4243-4e05-89d1-c6d1d5d868c1"></a> <a name=
"section-8.4" id="section-8.4"></a>
<h2>Adverse Reactions in Children</h2>
<p class="First">The pattern and incidence of adverse events and
laboratory abnormalities recorded during pediatric clinical trials
are comparable to those seen in adults.</p>
<p>In Phase II/III clinical trials conducted in the United States
and in Europe, 577 pediatric patients, ages 1 day to 17 years were
treated with fluconazole at doses up to 15 mg/kg/day for up to
1,616 days. Thirteen percent of children experienced
treatment-related adverse events. The most commonly reported events
were vomiting (5%), abdominal pain (3%), nausea (2%), and diarrhea
(2%). Treatment was discontinued in 2.3% of patients due to adverse
clinical events and in 1.4% of patients due to laboratory test
abnormalities. The majority of treatment-related laboratory
abnormalities were elevations of transaminases or alkaline
phosphatase.</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="24%">
<col width="16%">
<col width="26%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"
valign="middle">
<p class="First"><span class="Bold">Percentage of Patients With
Treatment-Related Side Effects</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Fluconazole</span><br>
<span class="Bold">(N = 577)</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Comparative Agents</span><br>
<span class="Bold">(N = 451)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">With any side effect</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">13.0</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">9.3</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Vomiting</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">5.4</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">5.1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Abdominal pain</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2.8</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1.6</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nausea</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2.3</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">1.6</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Diarrhea</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2.1</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">2.2</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name=
"i4i_overdosage_id_81ed1253-1cea-4476-9087-d31810e8688a" id=
"i4i_overdosage_id_81ed1253-1cea-4476-9087-d31810e8688a"></a>
<a name="section-9" id="section-9"></a>
<p class="First">There have been reports of overdose with
fluconazole accompanied by hallucination and paranoid behavior.</p>
<p>In the event of overdose, symptomatic treatment (with supportive
measures and gastric lavage if clinically indicated) should be
instituted.</p>
<p>Fluconazole is largely excreted in urine. A 3 hour hemodialysis
session decreases plasma levels by approximately 50%.</p>
<p>In mice and rats receiving very high doses of fluconazole,
clinical effects in both species included decreased motility and
respiration, ptosis, lacrimation, salivation, urinary incontinence,
loss of righting reflex, and cyanosis; death was sometimes preceded
by clonic convulsions.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name=
"i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14" id=
"i4i_dosage_admin_id_f972d350-8c08-470a-a23e-ec01b6248a14"></a>
<a name="section-10" id="section-10"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2029e36f-0a20-49dd-9737-501f854ddad9" id=
"i4i_section_id_2029e36f-0a20-49dd-9737-501f854ddad9"></a> <a name=
"section-10.1" id="section-10.1"></a>
<h2>Dosage and Administration in Adults</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d73300d1-6cb5-406e-b48e-881ad2b15f93" id=
"i4i_section_id_d73300d1-6cb5-406e-b48e-881ad2b15f93"></a> <a name=
"section-10.1.1" id="section-10.1.1"></a>
<h3><span class="Bold"><span class="Italics">Single
Dose</span></span></h3>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_c0f577d6-a231-45c3-b269-3a58bc4881cf" id=
"i4i_section_id_c0f577d6-a231-45c3-b269-3a58bc4881cf"></a> <a name=
"section-10.1.1.1" id="section-10.1.1.1"></a>
<h4>Vaginal Candidiasis</h4>
<p class="First">The recommended dosage of fluconazole tablets for
vaginal candidiasis is 150 mg as a single oral dose.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_baa163c0-8404-42d0-aa16-9f333c5e19da" id=
"i4i_section_id_baa163c0-8404-42d0-aa16-9f333c5e19da"></a> <a name=
"section-10.1.2" id="section-10.1.2"></a>
<h3><span class="Bold"><span class="Italics">Multiple
Dose</span></span></h3>
<p class="First">SINCE ORAL ABSORPTION IS RAPID AND ALMOST
COMPLETE, THE DAILY DOSE OF FLUCONAZOLE IS THE SAME FOR ORAL AND
INTRAVENOUS ADMINISTRATION. In general, a loading dose of twice the
daily dose is recommended on the first day of therapy to result in
plasma concentrations close to steady-state by the second day of
therapy.</p>
<p>The daily dose of fluconazole tablets for the treatment of
infections other than vaginal candidiasis should be based on the
infecting organism and the patient’s response to therapy. Treatment
should be continued until clinical parameters or laboratory tests
indicate that active fungal infection has subsided. An inadequate
period of treatment may lead to recurrence of active infection.
Patients with AIDS and cryptococcal meningitis or recurrent
oropharyngeal candidiasis usually require maintenance therapy to
prevent relapse.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_54b0a610-c66a-4b88-bd58-59ae455d3fc2" id=
"i4i_section_id_54b0a610-c66a-4b88-bd58-59ae455d3fc2"></a> <a name=
"section-10.1.2.1" id="section-10.1.2.1"></a>
<h4>Oropharyngeal Candidiasis</h4>
<p class="First">The recommended dosage of fluconazole tablets for
oropharyngeal candidiasis is 200 mg on the first day, followed by
100 mg once daily. Clinical evidence of oropharyngeal candidiasis
generally resolves within several days, but treatment should be
continued for at least 2 weeks to decrease the likelihood of
relapse.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_96d72c27-6c30-426a-822e-1dde2b9c62de" id=
"i4i_section_id_96d72c27-6c30-426a-822e-1dde2b9c62de"></a> <a name=
"section-10.1.2.2" id="section-10.1.2.2"></a>
<h4>Esophageal Candidiasis</h4>
<p class="First">The recommended dosage of fluconazole tablets for
esophageal candidiasis is 200 mg on the first day, followed by 100
mg once daily. Doses up to 400 mg/day may be used, based on medical
judgment of the patient’s response to therapy. Patients with
esophageal candidiasis should be treated for a minimum of 3 weeks
and for at least 2 weeks following resolution of symptoms.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2e965687-381a-4da1-bf8a-12ac0e8dd164" id=
"i4i_section_id_2e965687-381a-4da1-bf8a-12ac0e8dd164"></a> <a name=
"section-10.1.2.3" id="section-10.1.2.3"></a>
<h4>Systemic Candida Infections</h4>
<p class="First">For systemic <span class="Italics">Candida</span>
infections including candidemia, disseminated candidiasis, and
pneumonia, optimal therapeutic dosage and duration of therapy have
not been established. In open, noncomparative studies of small
numbers of patients, doses of up to 400 mg daily have been
used.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_30374261-8b32-4aa1-8394-3012e90f6f9e" id=
"i4i_section_id_30374261-8b32-4aa1-8394-3012e90f6f9e"></a> <a name=
"section-10.1.2.4" id="section-10.1.2.4"></a>
<h4>Urinary Tract Infections and Peritonitis</h4>
<p class="First">For the treatment of <span class=
"Italics">Candida</span> urinary tract infections and peritonitis,
daily doses of 50 mg to 200 mg have been used in open,
noncomparative studies of small numbers of patients.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_059b53e1-86e8-4e73-9e00-5bea4ed17843" id=
"i4i_section_id_059b53e1-86e8-4e73-9e00-5bea4ed17843"></a> <a name=
"section-10.1.2.5" id="section-10.1.2.5"></a>
<h4>Cryptococcal Meningitis</h4>
<p class="First">The recommended dosage for treatment of acute
cryptococcal meningitis is 400 mg on the first day, followed by 200
mg once daily. A dosage of 400 mg once daily may be used, based on
medical judgment of the patient’s response to therapy. The
recommended duration of treatment for initial therapy of
cryptococcal meningitis is 10 to 12 weeks after the cerebrospinal
fluid becomes culture negative. The recommended dosage of
fluconazole tablets for suppression of relapse of cryptococcal
meningitis in patients with AIDS is 200 mg once daily.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_2562babe-ce39-4fc1-83ea-f185d1f3f028" id=
"i4i_section_id_2562babe-ce39-4fc1-83ea-f185d1f3f028"></a> <a name=
"section-10.1.2.6" id="section-10.1.2.6"></a>
<h4>Prophylaxis in Patients Undergoing Bone Marrow
Transplantation</h4>
<p class="First">The recommended fluconazole tablet daily dosage
for the prevention of candidiasis in patients undergoing bone
marrow transplantation is 400 mg, once daily. Patients who are
anticipated to have severe granulocytopenia (less than 500
neutrophils per cu mm) should start fluconazole tablet prophylaxis
several days before the anticipated onset of neutropenia, and
continue for 7 days after the neutrophil count rises above 1,000
cells per cu mm.</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_e26f2087-933b-4f74-b699-bf0a7ecffda4" id=
"i4i_section_id_e26f2087-933b-4f74-b699-bf0a7ecffda4"></a> <a name=
"section-10.2" id="section-10.2"></a>
<h2>Dosage and Administration in Children</h2>
<p class="First">The following dose equivalency scheme should
generally provide equivalent exposure in pediatric and adult
patients:</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="20%">
<col width="9%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="2">
<dl class="Footnote">
<dt><a href="#footnote-reference-7" name="footnote-7" id=
"footnote-7">*</a></dt>
<dd>Some older children may have clearances similar to that of
adults. Absolute doses exceeding 600 mg/day are not
recommended.</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class=
"Underline">Pediatric Patients</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class=
"Underline">Adults</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">3 mg/kg</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">100 mg</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">6 mg/kg</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">200 mg</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">12<a class="Sup" href="#footnote-7" name=
"footnote-reference-7" id="footnote-reference-7">*</a> mg/kg</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">400 mg</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>Experience with fluconazole in neonates is limited to
pharmacokinetic studies in premature newborns. (See <a href=
"#i4i_clinical_pharmacology_id_56f7c3fa-f075-4ec5-aad7-e06f17f03a96">
CLINICAL PHARMACOLOGY</a>.) Based on the prolonged half-life seen
in premature newborns (gestational age 26 to 29 weeks), these
children, in the first 2 weeks of life, should receive the same
dosage (mg/kg) as in older children, but administered every 72
hours. After the first 2 weeks, these children should be dosed once
daily. No information regarding fluconazole pharmacokinetics in
full-term newborns is available.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_117ce67a-7425-4672-8358-ce090288572d" id=
"i4i_section_id_117ce67a-7425-4672-8358-ce090288572d"></a> <a name=
"section-10.2.1" id="section-10.2.1"></a>
<h3><span class="Bold"><span class="Italics">Oropharyngeal
Candidiasis</span></span></h3>
<p class="First">The recommended dosage of fluconazole for
oropharyngeal candidiasis in children is 6 mg/kg on the first day,
followed by 3 mg/kg once daily. Treatment should be administered
for at least 2 weeks to decrease the likelihood of relapse.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_d3d8cf00-bd64-4e57-9c73-6b5dc83e091c" id=
"i4i_section_id_d3d8cf00-bd64-4e57-9c73-6b5dc83e091c"></a> <a name=
"section-10.2.2" id="section-10.2.2"></a>
<h3><span class="Bold"><span class="Italics">Esophageal
Candidiasis</span></span></h3>
<p class="First">For the treatment of esophageal candidiasis, the
recommended dosage of fluconazole in children is 6 mg/kg on the
first day, followed by 3 mg/kg once daily. Doses up to 12 mg/kg/day
may be used, based on medical judgment of the patient’s response to
therapy. Patients with esophageal candidiasis should be treated for
a minimum of 3 weeks and for at least 2 weeks following the
resolution of symptoms.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_28a2b8f0-ee78-46dd-ad6e-267b3115f467" id=
"i4i_section_id_28a2b8f0-ee78-46dd-ad6e-267b3115f467"></a> <a name=
"section-10.2.3" id="section-10.2.3"></a>
<h3><span class="Bold"><span class="Italics">Systemic Candida
Infections</span></span></h3>
<p class="First">For the treatment of candidemia and disseminated
<span class="Italics">Candida</span> infections, daily doses of 6
to 12 mg/kg/day have been used in an open, noncomparative study of
a small number of children.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_14958942-6e2e-4410-ab4c-2f72814eb8a7" id=
"i4i_section_id_14958942-6e2e-4410-ab4c-2f72814eb8a7"></a> <a name=
"section-10.2.4" id="section-10.2.4"></a>
<h3><span class="Bold"><span class="Italics">Cryptococcal
Meningitis</span></span></h3>
<p class="First">For the treatment of acute cryptococcal
meningitis, the recommended dosage is 12 mg/kg on the first day,
followed by 6 mg/kg once daily. A dosage of 12 mg/kg once daily may
be used, based on medical judgment of the patient’s response to
therapy. The recommended duration of treatment for initial therapy
of cryptococcal meningitis is 10 to 12 weeks after the
cerebrospinal fluid becomes culture negative. For suppression of
relapse of cryptococcal meningitis in children with AIDS, the
recommended dose of fluconazole is 6 mg/kg once daily.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"i4i_section_id_42aba4e3-a8f7-4d50-a1a4-1967fe92ce7b" id=
"i4i_section_id_42aba4e3-a8f7-4d50-a1a4-1967fe92ce7b"></a> <a name=
"section-10.3" id="section-10.3"></a>
<h2>Dosage In Patients with Impaired Renal Function</h2>
<p class="First">Fluconazole is cleared primarily by renal
excretion as unchanged drug. There is no need to adjust single dose
therapy for vaginal candidiasis because of impaired renal function.
In patients with impaired renal function who will receive multiple
doses of fluconazole tablets, an initial loading dose of 50 mg to
400 mg should be given. After the loading dose, the daily dose
(according to indication) should be based on the following
table:</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col width="33%">
<col width="33%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class=
"Underline">Creatinine Clearance (mL/min)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First"><span class="Bold"><span class="Underline">Percent
of Recommended Dose</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">&gt;50</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">100%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">≤ 50 (no dialysis)</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">50%</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Regular dialysis</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">100% after each dialysis</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>Patients on regular dialysis should receive 100% of the
recommended dose after each dialysis; on non-dialysis days,
patients should receive a reduced dose according to their
creatinine clearance.</p>
<p>These are suggested dose adjustments based on pharmacokinetics
following administration of multiple doses. Further adjustment may
be needed depending upon clinical condition.</p>
<p>When serum creatinine is the only measure of renal function
available, the following formula (based on sex, weight, and age of
the patient) should be used to estimate the creatinine clearance in
adults:</p>
<div class="Figure"><a name="id2353" id="id2353"></a> <img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=b75dbe49-9a2a-4f8a-916a-42297c0b8f4f-02.jpg"
alt="Creatinine Clearance Calculation"></div>
<p>Although the pharmacokinetics of fluconazole has not been
studied in children with renal insufficiency, dosage reduction in
children with renal insufficiency should parallel that recommended
for adults. The following formula may be used to estimate
creatinine clearance in children:</p>
<div class="Figure"><a name="id2355" id="id2355"></a> <img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=b75dbe49-9a2a-4f8a-916a-42297c0b8f4f-03.jpg"
alt="Creatinine Clearance Formula for Children"></div>
<p><span class="Bold">Administration:</span> Fluconazole tablets
can be taken with or without food.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name=
"i4i_how_supplied_id_695e94a0-433e-44d8-94d2-532c0b091757" id=
"i4i_how_supplied_id_695e94a0-433e-44d8-94d2-532c0b091757"></a>
<a name="section-11" id="section-11"></a>
<p class="First">Fluconazole Tablets, USP are available containing
50 mg, 100 mg, 150 mg or 200 mg of fluconazole, USP.</p>
<p>The 50 mg tablets are yellow, round, unscored tablets debossed
with <span class="Bold">M</span> on one side of the tablet and
<span class="Bold">F3</span> on the other side. They are available
as follows:</p>
<p>NDC 0378-2514-93<br>
bottles of 30 tablets</p>
<p>The 100 mg tablets are yellow, round, unscored tablets debossed
with <span class="Bold">M</span> over <span class="Bold">F4</span>
on one side of the tablet and blank on the other side. They are
available as follows:</p>
<p>NDC 0378-2516-93<br>
bottles of 30 tablets</p>
<p>The 150 mg tablets are yellow, round, unscored tablets debossed
with <span class="Bold">M</span> over <span class="Bold">F5</span>
on one side of the tablet and blank on the other side. They are
available as follows:</p>
<p>NDC 0378-2518-96<br>
12 blister cards of 1 unit-dose tablet</p>
<p>The 200 mg tablets are yellow, round, unscored tablets debossed
with <span class="Bold">M</span> over <span class="Bold">F6</span>
on one side of the tablet and blank on the other side. They are
available as follows:</p>
<p>NDC 0378-2520-93<br>
bottles of 30 tablets</p>
<p><span class="Bold">Store at 20º to 25ºC (68º to 77ºF). [See USP
Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the
USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Patient
Information Leaflet with each prescription.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">REFERENCES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34093-5"><a name=
"i4i_references_id_99ba9a1a-8b3b-4e33-8f69-c42cbd8a5fbf" id=
"i4i_references_id_99ba9a1a-8b3b-4e33-8f69-c42cbd8a5fbf"></a>
<a name="section-12" id="section-12"></a>
<dl>
<dt>1.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Reference
Method for Broth Dilution Antifungal Susceptibility Testing of
Yeasts; Approved Standard-Third Edition. CLSI Document M27-A3,
Clinical and Laboratory Standards Institute, 940 West Valley Road,
Suite 1400, Wayne, PA, 19087, USA, 2008.</dd>
<dt>2.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Methods for
Antifungal Disk Diffusion Susceptibility Testing of Yeasts;
Approved Guideline-Second Edition. CLSI Document M44-A2, Clinical
and Laboratory Standards Institute, 940 West Valley Road, Suite
1400, Wayne, PA, 19087, USA, 2009.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PATIENT INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name=
"i4i_info_patients_id_03abec23-7aaf-46ad-ab57-b186f11b6d5b" id=
"i4i_info_patients_id_03abec23-7aaf-46ad-ab57-b186f11b6d5b"></a>
<a name="section-13" id="section-13"></a>
<p class="First"><span class="Bold">FLUCONAZOLE TABLETS, USP<br>
(floo kon' a zole)<br>
50 mg, 100 mg, 150 mg and 200 mg</span></p>
<p>This leaflet contains important information about fluconazole
tablets. It is not meant to take the place of your doctor’s
instructions. Read this information carefully before you take
fluconazole tablets. Ask your doctor or pharmacist if you do not
understand any of this information or if you want to know more
about fluconazole tablets.</p>
<p><span class="Bold">What Are Fluconazole Tablets?</span></p>
<p>Fluconazole is a tablet you swallow to treat vaginal yeast
infections caused by a yeast called <span class=
"Italics">Candida.</span> Fluconazole tablets help stop too much
yeast from growing in the vagina so the yeast infection goes
away.</p>
<p>Fluconazole tablets are different from other treatments for
vaginal yeast infections because it is a tablet taken by mouth.
Fluconazole tablets are also used for other conditions. However,
this leaflet is only about using fluconazole tablets for vaginal
yeast infections. For information about using fluconazole tablets
for other reasons, ask your doctor or pharmacist. See the section
of this leaflet for information about vaginal yeast infections.</p>
<p><span class="Bold">What Is A Vaginal Yeast Infection?</span></p>
<p>It is normal for a certain amount of yeast to be found in the
vagina. Sometimes too much yeast starts to grow in the vagina and
this can cause a yeast infection. Vaginal yeast infections are
common. About three out of every four adult women will have at
least one vaginal yeast infection during their life.</p>
<p>Some medicines and medical conditions can increase your chance
of getting a yeast infection. If you are pregnant, have diabetes,
use birth control pills, or take antibiotics you may get yeast
infections more often than other women. Personal hygiene and
certain types of clothing may increase your chances of getting a
yeast infection. Ask your doctor for tips on what you can do to
help prevent vaginal yeast infections.</p>
<p>If you get a vaginal yeast infection, you may have any of the
following symptoms:</p>
<dl>
<dt>•</dt>
<dd>itching</dd>
<dt>•</dt>
<dd>a burning feeling when you urinate</dd>
<dt>•</dt>
<dd>redness</dd>
<dt>•</dt>
<dd>soreness</dd>
<dt>•</dt>
<dd>a thick white vaginal discharge that looks like cottage
cheese</dd>
</dl>
<p><span class="Bold">What To Tell Your Doctor Before You Start
Fluconazole Tablets</span></p>
<p>Do not take fluconazole tablets if you take certain medicines.
They can cause serious problems. Therefore, tell your doctor about
all the medicines you take including:</p>
<dl>
<dt>•</dt>
<dd>diabetes medicines such as glyburide, tolbutamide,
glipizide</dd>
<dt>•</dt>
<dd>blood pressure medicines like hydrochlorothiazide, losartan,
amlodipine, nifedipine or felodipine</dd>
<dt>•</dt>
<dd>blood thinners such as warfarin</dd>
<dt>•</dt>
<dd>cyclosporine, tacrolimus or sirolimus (used to prevent
rejection of organ transplants)</dd>
<dt>•</dt>
<dd>rifampin or rifabutin for tuberculosis</dd>
<dt>•</dt>
<dd>astemizole for allergies</dd>
<dt>•</dt>
<dd>phenytoin or carbamazepine to control seizures</dd>
<dt>•</dt>
<dd>theophylline to control asthma</dd>
<dt>•</dt>
<dd>cisapride for heartburn</dd>
<dt>•</dt>
<dd>quinidine (used to correct disturbances in heart rhythm)</dd>
<dt>•</dt>
<dd>amitriptyline or nortriptyline for depression</dd>
<dt>•</dt>
<dd>pimozide for psychiatric illness</dd>
<dt>•</dt>
<dd>amphotericin B or voriconazole for fungal infections</dd>
<dt>•</dt>
<dd>erythromycin for bacterial infections</dd>
<dt>•</dt>
<dd>cyclophosphamide or vinca alkaloids such as vincristine or
vinblastine for treatment of cancer</dd>
<dt>•</dt>
<dd>fentanyl, afentanil or methadone for chronic pain</dd>
<dt>•</dt>
<dd>halofantrine for malaria</dd>
<dt>•</dt>
<dd>lipid lowering drugs such as atorvastatin, simvastatin, and
fluvastatin</dd>
<dt>•</dt>
<dd>non-steroidal anti-inflammatory drugs including celecoxib,
ibuprofen, and naproxen</dd>
<dt>•</dt>
<dd>prednisone, a steroid used to treat skin, gastrointestinal,
hematological or respiratory disorders</dd>
<dt>•</dt>
<dd>antiviral medications used to treat HIV like saquinavir or
zidovudine</dd>
<dt>•</dt>
<dd>tofacitinib for rheumatoid arthritis</dd>
<dt>•</dt>
<dd>vitamin A nutritional supplement</dd>
</dl>
<p>Since there are many brand names for these medicines, check with
your doctor or pharmacist if you have any questions.</p>
<dl>
<dt>•</dt>
<dd>are taking any over-the-counter medicines you can buy without a
prescription, including natural or herbal remedies</dd>
<dt>•</dt>
<dd>have any liver problems</dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd><span class="Bold">are pregnant, plan to become pregnant, or
think you might be pregnant. Your doctor will discuss whether
fluconazole tablets are right for you.</span></dd>
<dt>•</dt>
<dd>are breast-feeding. Fluconazole can pass through breast milk to
the baby.</dd>
<dt>•</dt>
<dd>are allergic to any other medicines including those used to
treat yeast and other fungal infections</dd>
<dt>•</dt>
<dd>are allergic to any of the ingredients in fluconazole tablets.
The main ingredient of fluconazole tablets is fluconazole. If you
need to know the inactive ingredients, ask your doctor or
pharmacist.</dd>
</dl>
<p><span class="Bold">Who Should Not Take Fluconazole
Tablets?</span></p>
<p>To avoid a possible serious reaction, do NOT take fluconazole
tablets if you are taking erythromycin, astemizole, pimozide,
quinidine, or cisapride (Propulsid<span class="Sup">®</span>) since
it can cause changes in heartbeat in some people if taken with
fluconazole tablets.</p>
<p><span class="Bold">How Should I Take Fluconazole
Tablets?</span></p>
<p>Take fluconazole tablets by mouth with or without food. You can
take fluconazole tablets at any time of the day.</p>
<p>Fluconazole tablets keep working for several days to treat the
infection. Generally the symptoms start to go away after 24 hours.
However, it may take several days for your symptoms to go away
completely. If there is no change in your symptoms after a few
days, call your doctor.</p>
<p><span class="Bold">Just swallow one fluconazole tablet to treat
your vaginal yeast infection.</span></p>
<p><span class="Bold">What Should I Avoid While Taking Fluconazole
Tablets?</span></p>
<p>Some medicines can affect how well fluconazole tablets work.
Check with your doctor before starting any new medicines within 7
days of taking fluconazole tablets.</p>
<p><span class="Bold">What Are The Possible Side Effects of
Fluconazole Tablets?</span></p>
<p>Like all medicines, fluconazole tablets may cause some side
effects that are usually mild to moderate.</p>
<p>The most common side effects of fluconazole tablets are:</p>
<dl>
<dt>•</dt>
<dd>headache</dd>
<dt>•</dt>
<dd>diarrhea</dd>
<dt>•</dt>
<dd>nausea or upset stomach</dd>
<dt>•</dt>
<dd>dizziness</dd>
<dt>•</dt>
<dd>stomach pain</dd>
<dt>•</dt>
<dd>changes in the way food tastes</dd>
</dl>
<p>Allergic reactions to fluconazole tablets are rare, but they can
be very serious if not treated right away by a doctor. If you
cannot reach your doctor, go to the nearest hospital emergency
room. Signs of an allergic reaction can include shortness of
breath; coughing; wheezing; fever; chills; throbbing of the heart
or ears; swelling of the eyelids, face, mouth, neck, or any other
part of the body; or skin rash, hives, blisters or skin
peeling.</p>
<p>Fluconazole tablets have been linked to rare cases of serious
liver damage, including deaths, mostly in patients with serious
medical problems. Call your doctor if your skin or eyes become
yellow, your urine turns a darker color, your stools (bowel
movements) are light-colored, or if you vomit or feel like vomiting
or if you have severe skin itching.</p>
<p>In patients with serious conditions such as AIDS or cancer, rare
cases of severe rashes with skin peeling have been reported. Tell
your doctor right away if you get a rash while taking fluconazole
tablets.</p>
<p>Fluconazole tablets may cause other less common side effects
besides those listed here. If you develop any side effects that
concern you, call your doctor. For a list of all side effects, ask
your doctor or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about
side effects. You may report side effects to FDA at
1-800-FDA-1088.</span></p>
<p><span class="Bold">What To Do For An Overdose</span></p>
<p>In case of an accidental overdose, call your doctor right away
or go to the nearest emergency room.</p>
<p><span class="Bold">How To Store Fluconazole Tablets</span></p>
<p>Store at room temperature between 20º to 25ºC (68º to 77ºF).<br>
Keep fluconazole tablets and all medicines out of the reach of
children.</p>
<p><span class="Bold">General Advice About Prescription
Medicines</span></p>
<p>Medicines are sometimes prescribed for conditions that are
mentioned in patient information leaflets. Do not use fluconazole
tablets for a condition for which they were not prescribed. Do not
give fluconazole tablets to other people, even if they have the
same symptoms you have. They may harm them.</p>
<p>This leaflet summarizes the most important information about
fluconazole tablets. If you would like more information, talk with
your doctor. You can ask your pharmacist or doctor for information
about fluconazole tablets that is written for health
professionals.</p>
<p>For more information, call Mylan Pharmaceuticals Inc. at
1-877-446-3679 (1-877-4-INFO-RX).</p>
<p>The brands listed are trademarks of their respective owners.</p>
<p>Manufactured for:<br>
<span class="Bold">Mylan Pharmaceuticals Inc.</span><br>
Morgantown, WV 26505 U.S.A.</p>
<p>Manufactured by:<br>
<span class="Bold">Mylan Laboratories Limited</span><br>
Hyderabad—500 034, India<br>
Code No.: MH/DRUGS/25/NKD/89</p>
<p>75051104</p>
<p>REVISED JANUARY 2016<br>
MX:FLCZ:R6p/MX:PL:FLCZ:R6p</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL – 50 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_8c2a5d6c-e280-4cc3-b8de-ccc7ad689427" id=
"ID_8c2a5d6c-e280-4cc3-b8de-ccc7ad689427"></a> <a name="section-14"
id="section-14"></a>
<p class="First"><span class="Bold">NDC 0378-2514-93</span></p>
<p><span class="Bold">Fluconazole<br>
Tablets, USP<br>
50 mg</span></p>
<p><span class="Bold">Rx only 30 Tablets</span></p>
<p>Each tablet contains:<br>
Fluconazole, USP 50 mg</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>
prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of<br>
the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>
[See USP Controlled Room<br>
Temperature.]</span></p>
<p>Manufactured for:<br>
<span class="Bold">Mylan Pharmaceuticals Inc.</span><br>
Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX2514H4</span></p>
<p>Dispense in a tight, light-resistant<br>
container as defined in the USP<br>
using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure"><a name="id478272366" id="id478272366"></a>
<img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=image-01.jpg"
alt="Fluconazole Tablets, USP 50 mg Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL – 100 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_f843abdd-aa12-47d1-8f83-afc97bc801f3" id=
"ID_f843abdd-aa12-47d1-8f83-afc97bc801f3"></a> <a name="section-15"
id="section-15"></a>
<p class="First"><span class="Bold">NDC 0378-2516-93</span></p>
<p><span class="Bold">Fluconazole<br>
Tablets, USP<br>
100 mg</span></p>
<p><span class="Bold">Rx only 30 Tablets</span></p>
<p>Each tablet contains:<br>
Fluconazole, USP 100 mg</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>
prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of<br>
the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>
[See USP Controlled Room<br>
Temperature.]</span></p>
<p>Manufactured for:<br>
<span class="Bold">Mylan Pharmaceuticals Inc.</span><br>
Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX2516H5</span></p>
<p>Dispense in a tight, light-resistant<br>
container as defined in the USP<br>
using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure"><a name="id1523510886" id="id1523510886"></a>
<img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=image-02.jpg"
alt="Fluconazole Tablets, USP 100 mg Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL – 150 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_bc6b0939-fe05-4938-8e1c-2296d07f1907" id=
"ID_bc6b0939-fe05-4938-8e1c-2296d07f1907"></a> <a name="section-16"
id="section-16"></a>
<p class="First"><span class="Bold">Fluconazole Tablet USP, 150
mg</span></p>
<p><span class="Bold">NDC 0378-2518-96 Rx only 12 Cartons x 1
Unit-dose Tablet</span></p>
<p><span class="Bold">Each tablet contains:</span><br>
Fluconazole, USP ....... 150 mg</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>
prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>
[See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light. Store blisters in
carton.</span></p>
<p><span class="Bold">Do not use if blister is torn, broken, or
missing.</span></p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<p>Manufactured for:<br>
<span class="Bold">Mylan Pharmaceuticals Inc.</span><br>
Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">www.mylan.com</span></p>
<p><span class="Bold">MX2518-96-12C:R4</span></p>
<div class="Figure"><a name="id-963194077" id="id-963194077"></a>
<img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=image-03.jpg"
alt="Fluconazole Tablets, USP 150 mg Carton Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL – 200 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_905090e1-78c1-4fed-a548-d970ffcf39bf" id=
"ID_905090e1-78c1-4fed-a548-d970ffcf39bf"></a> <a name="section-17"
id="section-17"></a>
<p class="First"><span class="Bold">NDC 0378-2520-93</span></p>
<p><span class="Bold">Fluconazole<br>
Tablets, USP<br>
200 mg</span></p>
<p><span class="Bold">Rx only 30 Tablets</span></p>
<p>Each tablet contains:<br>
Fluconazole, USP 200 mg</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>
prescribing information.</p>
<p><span class="Bold">Keep this and all medication out of<br>
the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>
[See USP Controlled Room<br>
Temperature.]</span></p>
<p>Manufactured for:<br>
<span class="Bold">Mylan Pharmaceuticals Inc.</span><br>
Morgantown, WV 26505 U.S.A.</p>
<p>Made in India</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RMX2520H5</span></p>
<p>Dispense in a tight, light-resistant<br>
container as defined in the USP<br>
using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Code No.: MH/DRUGS/25/NKD/89</p>
<div class="Figure"><a name="id-1267528957" id="id-1267528957"></a>
<img src=
"image.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69&amp;name=image-04.jpg"
alt="Fluconazole Tablets, USP 200 mg Bottle Label"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FLUCONAZOLE</strong><br>
<span class="contentTableReg">fluconazole tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-2514</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FLUCONAZOLE</strong> (UNII:
8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)</td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">50 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII:
ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII:
35SW5USQ3G)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;F3</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0378-2514-93</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076351</td>
<td class="formItem">07/29/2004</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FLUCONAZOLE</strong><br>
<span class="contentTableReg">fluconazole tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-2516</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FLUCONAZOLE</strong> (UNII:
8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)</td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">100 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII:
ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII:
35SW5USQ3G)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;F4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0378-2516-93</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076351</td>
<td class="formItem">02/26/2013</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FLUCONAZOLE</strong><br>
<span class="contentTableReg">fluconazole tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-2518</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FLUCONAZOLE</strong> (UNII:
8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)</td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">150 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII:
ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII:
35SW5USQ3G)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;F5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0378-2518-96</td>
<td class="formItem">12 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0378-2518-32</td>
<td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076351</td>
<td class="formItem">02/26/2013</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>FLUCONAZOLE</strong><br>
<span class="contentTableReg">fluconazole tablet</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-2520</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FLUCONAZOLE</strong> (UNII:
8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)</td>
<td class="formItem">FLUCONAZOLE</td>
<td class="formItem">200 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong> (UNII:
3SY5LH9PMK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong> (UNII:
ETJ7Z6XBU4)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong> (UNII:
35SW5USQ3G)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong>
(UNII: OP1R32D61U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;F6</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0378-2520-93</td>
<td class="formItem">30 in 1 BOTTLE, PLASTIC; Type 0: Not a
Combination Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076351</td>
<td class="formItem">02/26/2013</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Mylan Pharmaceuticals Inc.
(059295980)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22FLUCONAZOLE%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=FLUCONAZOLE"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=FLUCONAZOLE"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00327&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">FLUCONAZOLE- fluconazole tablet<br></h3>
<h4>Number of versions: 7</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Feb 1, 2016</td>
<td>8 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=202068">download</a></td>
</tr>
<tr>
<td>Feb 27, 2013</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=101441">download</a></td>
</tr>
<tr>
<td>Sep 23, 2011</td>
<td>6</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=63824">download</a></td>
</tr>
<tr>
<td>Dec 16, 2010</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=44330">download</a></td>
</tr>
<tr>
<td>Nov 19, 2010</td>
<td>4</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=42853">download</a></td>
</tr>
<tr>
<td>Dec 15, 2009</td>
<td>3</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=14390">download</a></td>
</tr>
<tr>
<td>May 4, 2007</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=4125">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">FLUCONAZOLE- fluconazole tablet<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197698">197698</a></td>
<td>fluconazole 100 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197698">197698</a></td>
<td>Fluconazole 100 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197699">197699</a></td>
<td>fluconazole 150 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197699">197699</a></td>
<td>Fluconazole 150 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197700">197700</a></td>
<td>fluconazole 200 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197700">197700</a></td>
<td>Fluconazole 200 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197701">197701</a></td>
<td>fluconazole 50 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=197701">197701</a></td>
<td>Fluconazole 50 MG Oral Tablet</td>
<td>SCD</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">FLUCONAZOLE- fluconazole tablet<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=cf26b007-df4f-4936-b2d3-183969761f69</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AFLUCONAZOLE%2D%20Fluconazole%20Tablet%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Dcf26b007%2Ddf4f%2D4936%2Db2d3%2D183969761f69%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "FLUCONAZOLE- fluconazole tablet <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
